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1. INTRODUCTION
Leukaemia, especially the acute types predominant in children, may be caused by ionizing
radiation. The large scale epidemiological studies of the cohort that had been exposed in
Hiroshima and Nagasaki (Life Span Study) show a significantly increased risk of leukaemia
among the survivors [TOM 93]. Altogether, 290 cases of leukaemia were observed between
1950 and the end of 1987 among 93 696 survivors accounting for 2 778 000 person years
[PRE 94]. A dose could be attributed to 231 of the 290 cases. Of the 231 cases taken into the
analysis, 75 cases were estimated to be due to the radiation [PRE 94]. This induction of
tumours of the haematopoetic system is the most important stochastic health effect even at
low radiation doses [SHI 95, PIE 96].
The relative risk (RR) of leukaemia (ALL, AML and CML – no increase of CLL has been
observed in Japan) at 1 Sievert is 6.13, as compared to a RR of all solid tumours at 1 Sievert
of 1.63. The relative risks at 1 Sievert for the different types of leukaemia vary from 4.3
(AML) to 7.2 (CML) and 10.1 (ALL) [PRE 94, THO 94]. The excess relative risk of
leukaemia at 1 Sievert (ERR1Sv 5.13) is 8.14 times the excess relative risk of all solid tumours
at 1 Sievert (ERR1Sv 0.63) [PRE 94]. This risk induction is detectable for doses of 200 mSv or
more [DOL 98], whereas the risk at lower doses is disputable, but may be present from as
little as 50 – 100 mSv [PIE 96]. The general pattern of cancer incidence in the exposed
Japanese cohort showed men to have higher relative risks than women and the risks tended to
be higher for those exposed at younger ages [PRE 94]. A British study of children whose
mothers had been x-rayed during pregnancy found that the leukaemia risk up to the age of 15
was 40% above the spontaneous rate even at doses of 10-20 mSv [STE 56].
Due to problems with case ascertainment and the determination of population size in
Hiroshima and Nagasaki it is impossible to compute risk estimates for leukaemia for the years
before 1948 [PRE 94]. When the Life Span Study cohort was first established in 1950,
however, an increase of leukaemia was evident and peaked in the period 1950-1953 [SHI 95].
Estimates on leukaemia incidence in the years 1948-1950, however, already show an increase
in incidence rates which are based on untyped cases obtained from the Leukaemia Registry
[FOL 52]. An increase of leukaemia incidence may thus be expected after a latency of about
two years with the highest risk occurring five to eight years after irradiation [PRE 94],
whereas the incidence of solid tumours begins to increase only after a latency of ten years.
Even more than 30 years after the bombings, the incidence rates both of leukaemia (except
CLL) and solid tumours among those affected are higher than in the remainder of Japan [PRE
94, THO 94].
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1.1. LEUKAEMIA – A SHORT OVERVIEW
1.1.1. DEFINITION
The term leukaemia goes back both to Rudolph Virchow and John Bennett who described the
predominance of leukocytes in the blood of patients with chronic myeloid leukaemia (CML)
as white blood first in 1845 [BEN 03, VIR 03]. Leukaemia designates several malignant
disease entities of the haematopoetic or lymphopoetic system with uncontrolled clonal
proliferation and/or altered pathways of apoptosis at distinct stages of haematopoesis.
1.1.2. CLASSIFICATION
Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) are clonal
disorders of early myeloid or lymphoid precursors. ALL can be distinguished
immunologically into B-cell or T-cell precursors of different stages of differentiation. There
are different prognostic subgroups according at least partly to certain cytogenetic alterations.
AML can be classified morphologically into 6 different types. However, there are several
known cytogenetic aberrations in AML which are prognostically more important than the
morphological subtype. AML with balanced translocations (e.g. t(15;17), t(8;21)) belongs to
the low risk group concerning a relapse after therapy, whereas AML with complex karyotypes
with gain or loss of chromosomal material is prognostically unfavourable. Generally, AML is
classified into primary and secondary forms. AML occurring after chemo- or radiotherapy or
in the course of myelodysplastic syndromes is defined as secondary leukaemia. Radiation-
associated Leukaemia shows complex karyotypes more frequently than leukaemia after
chemotherapy and therefore has a worse prognosis. Whether AML which was induced as a
consequence of a nuclear accident belongs to this risk group remains to be determined.
Chronic myeloid leukaemia (CML) is a clonal disease of an early pluripotent stem cell with a
characteristic cytogenetic defect, the Philadelphia chromosome, which is the result of a
balanced reciprocal translocation between chromosome 9 and 22. On the molecular level, abl
is translocated from chromosome 9 to the breakpoint cluster region (bcr) of chromosome 22.
The resulting hybrid gene bcr-abl leads to the expression of a deregulated tyrosinkinase. The
consequences of its activity are:
• alteration of adhesion to the bone marrow stroma
• activation of mitogenic signals
• inhibition of apoptosis
• deregulation of inhibitory proteins
This cytogenetic defect appears at such an early stage of haematopoesis that it affects
granulopoesis (including eosinophils and basophils), as well as erythropoesis,
megakaryopoesis, B-lymphocytes and – in rare events – even T-cells. The bcr-abl
rearrangement can then be found in all of these cells. Additional cytogenetic events in the
course of the disease lead to its progression, resulting in an accelerated phase and finally a
blast crisis [WAT 03].
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Leukaemic cells in chronic lymphatic leukaemia (CLL) appear mostly as morphologically
mature B-cells. The stage of differentiation of the neoplastic cells corresponds to a circulating
mature but antigen-naive B-cell. These clonal B-cells are immunoincompetent, the
proliferation is slow and the survival longer than in normal B-cells. The disease is frequently
associated with autoimmune phenomena such as autoimmune haemolysis or immune
thrombocytopaenia. The risk of secondary solid tumours is enhanced compared with normal
controls. Although there are certain cytogenetic alterations associated with a worse prognosis,
the course of the disease is generally benign in comparison to the other types of leukaemia
[WAT 03].
1.1.3. EPIDEMIOLOGY
Leukaemia incidence rates in children are astonishingly similar throughout the world. The
mean annual age-standardized incidence rates in the 28 European registries presented by
IARC lie between 3.3/100 000 (Bulgaria) and 5.3/100 000 (Denmark). The risk is slightly
higher for boys than for girls. About 75-80% of leukaemia in children is ALL, 20-25% AML.
The share of chronic leukaemia does not exceed 2-3%, most of which are of myeloid form
[PAR 98]. However, a few cases of CLL are also documented [YOF 90, SON 83]. Acute
leukaemia shows a characteristic peak in incidence between the ages of two and five years.
The age-specific incidence subsequently declines to about 2/100 000, where it remains stable
during childhood and adolescence [DKR 00].
In adults, the distribution of ALL and AML is exactly the opposite as in children: 80% of
acute leukaemia type as AML, 20% as ALL. The mean age for incurring AML is 62 years,
whereas the incidence of ALL, apart from the peak at age three, remains moderate at about
2/100 000 [IME 98, SEE 03].
Predominant in adults are the chronic forms of leukaemia, CLL and CML, which occur in a
ratio of 2:1 respectively. There is a male predominance for both [FIN 92]. The mean
incidences in adults are 2-3/100 000 for CLL and 1-1.5/100 000 for CML [IME 94]. Age-
specific incidence rates increase with age. This increase starts after the age of 40 and the
acceleration is about twice the rate in CLL than in CML [SEE 03]. Figure 1.2 shows the age-
specific incidence rates for all leukaemia and for the different forms separately.
Despite their incurability, the overall prognosis is best for chronic leukaemia. The median
survival of patients with CLL is more than five years [TEF 92], based on a survival between 2
(stage III) and 13 (stage 0) years depending on the stage [RAI 90]. Patients with de novo
CML show a median survival of 3.5 years [COR 95]. For 1985-1989, EUROCARE reports
weighted age-standardized 5-year survival rates for Europe of 63% (CLL), 31% (CML), 25%
(ALL), 10% (AML). Survival had improved compared with 1978-1980 for CLL, AML and
ALL, only CML showed little improvement. Poorer survival rates are reported for the Eastern
European countries. The relative survival declines with age and this effect is most marked in
patients with acute leukaemia. [CAR 98].
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Fig 1.2 Age-specific incidence rates for leukaemia [SEE 03] (*SEER: Surveillance, Epidemiology and
End Results). Figure by Elke Nekolla.
1.1.4. RISK FACTORS OTHER THAN RADIATION
Apart from radiation, which has been shown to increase the risk of CML, AML and ALL in
various cohorts [LIT 99b, WIC 99] – an influence on CLL is recently also being discussed
[LAM 98, LOU 98, GLU 01, IMA 01] – various substances and other factors may have a role
in inducing leukaemia.
The past decades have seen remarkable progress in the understanding of the biological
features and, consequently, in the therapeutic approaches towards leukaemia. Nevertheless, no
one main risk factor has so far been identified. Even the established risk factors often increase
the risk only marginally and studies concerning a multitude of possible risk factors show
contradictory results. Anyway, under the assumption of a model of tumourgenesis with - at
least - one mutation and one promotion [GRE 93b] it is implausible to assume the influence of
but one causal factor.
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For acute leukaemia, there are a number of established risk factors such as ionizing radiation,
certain genetic constellations like Down’s syndrome, Ataxia teleangiectasia, Fanconi’s
anaemia, type I neurofibromatosis, HTLV I (for adult T-cell leukaemia). Other factors are still
under discussion: electromagnetic fields, factors associated with the immune system like little
early infections or allergies and immunisation (both protective) and chemicals like benzene or
pesticides [BEC 02, SCH 02]. As to acute leukaemia in children, the idea that infections
might play a role in their induction had been discussed at the beginning of the last century, but
was later dismissed. This idea has lately been revived and further developed mainly by two
authors. Greaves postulates an initial mutation in a B-precursor cell in-utero, where
proliferation is high. One or more further mutation(s) then supposedly take place after birth
under the influence of an infectious agent. These mutations are strongly dependant on the type
of the agent and the moment of the influence [GRE 93a, GRE 97]. Kinlen proposes an
aberrant response model in which an infection with some known ubiquitous virus takes place
early in childhood or even in-utero and – as a very rare event – induces leukaemia. This is
especially believed to be true for formerly secluded populations which now undergo
population mixing [ALE 93, KIN 95, MAC 92].
Even less is known about the aetiology of chronic leukaemia. CLL shows a genetic
component: there is a known familial risk as well as an increased risk in persons with trisomie
12 [WIE 01] and incidence among Asians is very low [FIN 92]. Studies concerning the
influence of electromagnetic fields [FLO 93], benzene, pesticides and solvents remain
contradictory [ZHE 02, ADA 99, RAA 96, FIN 92]. Only a viral aetiology is undisputed for
certain types of chronic T-cell leukaemia which are known to be associated with HTLV I and
possibly HTLV II [FIN 92].
For CML, there is a greater incidence in Blacks than in Whites, yet otherwise little evidence
for a strong genetic component [FIN 92]. Benzene is widely accepted as a causative factor,
but results in different studies are not entirely consistent [NOR 97, YIN 96]. The same applies
to organic solvents and electromagnetic fields [BJO 01]. Similar to AML, there may be an
increased risk of CML after chemotherapy, but further studies are required on this topic [BAU
02].
1.2. SITUATION AFTER THE CHERNOBYL NUCLEAR POWER PLANT ACCIDENT
The accident in the Chernobyl Nuclear Power Plant in Northern Ukraine that occurred on 26
April 1986 was the largest accident so far in the history of civil use of atomic energy. The
accident and the subsequent fire in the reactor led to the release of large amounts of
radioactive materials with an activity of 12 Exabecquerel (1018 Becquerel). Radionuclides
such as 131Iodine, 134Caesium, 137Caesium were dispersed over large parts of Europe
depending on the wind and precipitation conditions. The most highly contaminated regions
are in Belarus, the Western parts of Russia and the Northern Ukraine. The population in these
regions is subject to persisting external exposure as well as internal exposure through
radioactive foodstuffs. About 6.7 million people live in regions with levels of ground
contamination with radiocaesium of 37 000 Bq/m² or more at the time of the accident, 1.4
million of which live in regions with levels of ground contamination of 185 000 Bq/m² or
more, one fifth to one sixth are children under the age of 15.
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There are two different kinds of exposure situations that need to be considered separately in
the assessment of the long-term health effects of the Chernobyl accident:
The very large releases of short-lived radioiodine led to high doses in the thyroid gland.
Prophylactic intake of stable iodine in the first days after the accident was not made available
to the population in the immediately affected regions. Since the doses were accumulated in
the first days and weeks after the accident, there was no possibility of subsequent remedial
action. Consequently, a dramatic increase in thyroid carcinomas, especially in those who were
children at the time, was later observed [RAR 99]. This is the one grave health effect directly
due to the Chernobyl reactor accident.
Long-lived radioactivity, mainly from radiocaesium, led to continued low dose rate exposure
of the inhabitants of the affected regions. This long-term exposure of large groups of the
population was the major aspect that led to evacuations, restrictions in food production and
consumption, and to general disruption. It remains an important issue in public health policy
and public opinion. Persisting grave apprehensions are still focused on the continued exposure
to radiation and on possible increases of cancer incidence, of hereditary defects and
congenital malformations and – at least in the collective perception – even of general
morbidity.
A lack of verifiable and comparable data and scientific publications makes the assessment of
health effects in Belarus, Russia and the Ukraine due to the continued low radiation exposure
after the Chernobyl accident very difficult. Particularly disastrous was the restrictive
information policy of the Soviet government in the years following the accident: scarce and
contradictory information led to misinformation and an overwhelming feeling of helplessness
among the affected population who now tend to mistrust all information from official sources.
To date, a distorted picture of real or supposed risks is often presented in the Western and
Eastern press as well as in international scientific journals [e.g. PET 96 in Nature], which
leads to further uncertainty: many of the affected persons now attribute any illness or
unwellness to the radiation. The unresolved questions and remaining uncertainties have
evoked continuous stress among the affected population and the resulting concerns and
anxieties contributed to a deterioration in the living conditions and the quality of life in the
affected regions. It is necessary to investigate further in order to provide reliable information
as a basis for remedial action and effective counter-measures wherever these may be required.
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1.3. STUDY FRAMEWORK AND TIMETABLE
In view of this situation, the German and French Ministers of the Environment, Angela
Merkel and Corinne Lepage initiated the German-French Initiative for Chernobyl (GFI). The
initiative comprises projects in the fields of
• safety of the sarcophagus
• radioecology
• health effects
The programme is being financed by the governments as well as by German and French
electric power companies, Electricité de France (EDF) and Verband der Elektrizitätswerke
(VDEW), with an overall budget of approximately 6 million Euro.
The main purpose of the GFI is to assist in the collection and validation of the existing data in
the three most highly contaminated countries, Belarus, Russia and the Ukraine, to constitute a
reliable and objective basis of information useful to the planning of countermeasures, for
informing the public, and for future scientific work. In the health effects projects, the main
aim is to obtain comparable data from the three countries using similar methodologies. It is
essential that the data be of continuously high quality in order to allow a joint analysis. This
will increase the power of the studies and thus the probability of obtaining reliable results.
The German Company for Plant and Reactor Safety (Gesellschaft für Reaktorsicherheit, GRS)
is responsible for carrying out the GFI on the German side with the exception of the health
effects projects – altogether eleven – which have been planned and implemented by the
Radiobiological Institute of the University of Munich.
The data of the present thesis were obtained within the framework of subproject 3.2.4.:
Leukaemia Incidence Among Children and Adults in the Most Highly Contaminated
Territories of Russia, which started in April 1999 and ended as scheduled after three years in
March 2002.
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1.4. STUDY GOAL AND TECHNIQUE
The South-western parts of the Russian Federation, especially parts of the Bryansk and
Kaluga oblasts, were contaminated due to the Chernobyl Nuclear Power Plant accident.
The objective of this study is to investigate whether there has been an increase in the
incidence of leukaemia in the general population of these regions and whether and how such a
possible increase may be linked to the radiation factor. To this end, a prospective cohort study
with a control group was carried out for the years 1980 to 1998.
Cancer cases in the Soviet Union were registered in centralized, population-based cancer
registries. The same applies to the Commonwealth of Independent States (CIS) from
December 1991. The data that form the basis of this study were taken from the statistics
departments of the oncological dispensaries of the Bryansk and Kaluga oblasts. They were
ascertained, verified and validated together with the Radiobiological Institute of the
University of Munich (LMU).
All cases of leukaemia that occurred between 1980 and 1998 in the affected regions of Russia
(five rayons of the Bryansk oblast and 3 rayons of the Kaluga oblast) and the complete data
from a neighbouring control region (3 rayons of the Kaluga oblast) - altogether 333 cases –
are included in the analysis.
The main questions addressed in the present study are the following:
• are the data complete and of sufficiently high quality?
• is there a continuous documentation or an indication of an expectation or detection bias?
• what are the strengths and the limitations of the study?
• what are the estimated attributable risks of leukaemia in the study cohort and would these
hypothetical cases be detectable against the fluctuation of the baseline cases?
• are the incidence rates in the population of the contaminated rayons similar to those of the
populations in the control rayons?
• is there a secular trend in the incidence rates in the population of the contaminated rayons
and, if so, are the rates after the accident considerably higher than before?
• are the results in line with the radiobiological experience or do they contradict the present
risk co-efficients for radiation [UNS 94]?
• are the findings relevant in view of a public health approach and what do they imply?
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2. MATERIALS AND METHODS
2.1. DEFINITION OF THE STUDY PERIOD
The study period was chosen to be 1980 – 1998, allowing a sufficiently realistic picture of the
leukaemia incidence in the years before the accident to be achieved. It is further divided into
three periods for various reasons:
Pooled time periods provide larger sample sizes and therefore higher power for the analysis of
a possible secular trend. In view of this it is advantageous to divide the period in a way that
produces approximately equal sample sizes.
Furthermore, both a possible expectation as well as a detection bias could be revealed only if
a minimum of two consecutive post-accident periods were analysed. Both biases would lead
to elevated incidence rates directly after the accident and a subsequent decrease. In the case of
an expectation bias the incidence rates would simply return to the pre-accident level. In the
case of a detection bias the rates would fall below the pre-accident rates after the initial
increase before returning to the actual level.
Last, but not least, the time pattern of leukaemia occurrence after irradiation [SHI 95]
proposes a division into an earlier and a later post-accident period: an increase in the
incidence of leukaemia (excluding CLL) after irradiation can be observed after a latent period
of about two years [PRE 94] with a peak of radiation-induced leukaemia occurring about five
to eight years after irradiation [SHI 95].
Considering all of the above, it seemed suitable to choose the periods as follows:
• a pre-accident period (1980–1986)
• an early post-accident period (1987-1992)
• a late post-accident period (1993-1997)
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2.2. RADIOLOGICAL SITUATION
2.2.1. CONTAMINATION
The Chernobyl Nuclear Power Plant accident on 26 April 1986 was the largest accident in the
civil use of atomic energy. It led to the contamination of vast territories of Europe, especially
of the former Soviet Union, and Scandinavia.
The contamination of Russia started on 28 April 1986 when north-easterly winds blew the
radioactive cloud over from the Ukraine. Due to the intensive rainfalls (10 mm/h) over the
boundary between the Mogilev and Gomel oblasts of Belarus and the Bryansk oblast of
Russia on 28-29 April 1986 the large Bryansk-Belarus spot was formed. The rain washed out
radionuclides from the radioactive cloud. This increased the speed of deposits of
radionuclides on the soil leading to uneven, in some places high levels of contamination in the
Bryansk and Kaluga oblasts.
The radioactive cloud remained over the south-western rayons of the Bryansk oblast for 13
hours from the afternoon of 28 April until 7 a.m. of 29 April 1986. It moved on to the east in
the direction of Tula city and covered the territory of southern rayons of Kaluga oblast. The
maximum level of radioactive contamination of the Tula-Kaluga-Oriol spot was lower by an
order of magnitude compared to that of the Bryansk-Belarus spot. This is assumed to be due
to an expansion of the cloud and its exhaustion after the previous deposits.
The level of exposure of the population of the three oblasts to radiation - especially in 1986 –
was taken into account by the national and local authorities when decisions concerning
radiation protection were made. These decisions were based on information from intensive
radiation surveillance carried out from May 1986 by central and local bodies and institutions
affiliated to the Goskomgidromet of the USSR (State Committee of Hydrometeorology of the
USSR), the Ministry of Public Health of the Russian Federation and Gosagroprom (State
Committee of Agricultural Industry).
Detailed maps based on the official data [MER 96] of the average density of 137Cs
contamination of the Bryansk and the Kaluga oblasts are given in figs. 2.1-2.2.
Fig 2.1 Official average density of 137Cs contamination f the Bryansk oblast [MER 96]
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Fig 2.2 Official average density of 137Cs contamination in the Kaluga oblast [MER 96]
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2.2.2. DOSES RECEIVED BY THE POPULATION
From the beginning of radioactive fall-out, the population was exposed externally and
internally to a mixture of various products of fission and activation. Radioisotopes of iodine
and caesium, as well as of strontium and plutonium, were the most significant contributors.
Radiation monitoring was designed to estimate the density of soil contamination with long-
lived radionuclides, such as 137Cs, 90Sr and isotopes of plutonium, in the settlements and
surrounding territories; air concentration was measured as well. Radionuclide composition
was studied, exposition dose rate from γ-radiation was measured, foodstuffs and water were
tested for radionuclides, and whole body counts were performed. All this information allowed
an estimation of the current annual doses to the population. However, it was very difficult to
estimate radiation doses accumulated during the first year after the accident. At that time
dozens of radionuclides with different radiological properties contributed to the dosimetry.
The temporal changes of the radiation situation were rapid and depended on local
environmental and social conditions.
Table 2.1 compiles some important characteristics of the radionuclides which reached the
territory of the Russian Federation as a result of atmospheric transfer.
Table 2.1 Radionuclides deposited on the territory of Russia after the Chernobyl accident
Radionuclide Period of half-life
Mother
(m)
Type of
radiation
Daughter
(d)
Type of
radiation Tmother Tdaughter
Final stable
isotope
137Cs β 137mBa β+γ 30.2 years 156 seconds 137Ba
136Cs β+γ − − 13.1 days − 136Ba
134Cs β+γ − − 2.1 years − 134Ba
89Sr β − − 53.6 days − 89Y
90Sr β 90Y β+γ 28 years 64.3 hours 90Zr
131I β+γ − − 8.0 days − 131Xe
132Te β+γ 132I β+γ 3.3 days 2.3 hours 132Xe
133I β+γ 133Xe β+γ 0.9 days 5.3 days 133Cs
140Ba β+γ 140La β+γ 12.7 days 1.7 days 140Ce
95Zr β+γ 95Nb β+γ 64.0 days 35.2 days 95Mo
103Ru β+γ 103mRh β+γ 39.3 days 0.9 hours 103Rh
106Ru β 106Rh β+γ 1.0 years 3 seconds 106Pd
141Ce β+γ − − 32.5 days − 141Pr
143Ce β+γ 143Pr β+γ 1.4 days 13.6 days 143Nd
144Ce β+γ 144Pr β+γ 0.8 years 0.3 hours 144Nd
125Sb β+γ 125mTe β+γ 2.8 years 58.0 days 125Te
99Mo β+γ 99mTc β+γ 2.8 days 6.0 hours 99Ru
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Radionuclides with a half-life of less than one month decayed completely during the first year
after the accident. Since the level of contamination of the soil with long-lived radioisotopes
such as 95Zr+95Nb, 106Ru+106Rh, 144Ce+144Pr and 125Sb was low, their contribution to the
radiological situation after April 1987 is negligible.
For 5-7 years from April 1987, the main contributors to radioactive contamination of the
territory were 137Cs and 134Cs. Whereas the contribution of 134Cs to radioactive contamination
decreased rapidly, the situation at present is determined by 137Cs-contamination of the soil and
environment (figs. 2.1 and 2.2).
To estimate radiation risks of leukaemia, effective doses both from internal and external
exposure to the whole body should be accounted for. The procedure for estimation of the
above doses was developed in Russia in 1996 by specialists of the Institute of Radiation
Hygiene of the Ministry of Health of the Russian Federation (St.-Petersburg), the Medical
Radiological Research Centre of the Russian Academy of Medical Sciences, the Institute of
Biophysics of the State Research Centre of the Russian Federation, and the Scientific and
Productive Association Taifoon of Rosgydromet. Their findings are documented as
Reconstruction of the Mean Effective Dose (accumulated for 1986-1995) to the Population of
the Settlements of the Russian Federation Affected by Radioactive Contamination as a Result
of the Accident at the Chernobyl NPP [MER 96].
Based on these methodological recommendations, official data on the mean effective doses
from external and internal exposure to the whole body of residents of the settlements of the
Bryansk and Kaluga oblasts were estimated. The results of these estimations were discussed
and adopted at the session of the Russian Scientific Commission on Radiation Protection in
1996.
About 90% of the total additional doses following the Chernobyl catastrophe were
accumulated in the ten years from 1986 - 1995. The mean cumulative effective doses over 9.7
years were calculated for the population of 1 091 contaminated settlements (soil
contamination over 37 kBq/m2) of the Bryansk oblast and 404 contaminated settlements of
the Kaluga oblast. Estimates of the mean cumulative doses received by the residents of these
settlements in the Bryansk oblast are within the range of 4-167 mSv, for the residents of these
settlements in the Kaluga oblast within the range of 1.4-25 mSv. The mean cumulative
effective doses are given in table 2.2.
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Table 2.2 Settlements of the Bryansk and the Kaluga oblasts with mean 137Cs contamination
density above 37 kBq/m2 and the integrated mean cumulative effective dose
(mSv) of internal and external exposure received by adults (1986 to December 31,
1995)
Range of the mean cumulative effective dose
(mSv)
Lower limit Upper limit
Number of
settlements Percentage (%)
The entire Bryansk oblast : 1 091 settlements; mean cumulative effective dose 23.5 ± 19.2 mSv
3 4 2 0.2
4 5 40 3.7
5 7 110 10.1
7 10 148 13.6
10 15 201 18.4
15 20 118 10.8
20 25 95 8.7
25 30 84 7.7
30 40 101 9.3
40 50 86 7.9
50 70 81 7.4
70 100 15 1.4
100 150 10 0.9
150 200 1 0.1
The entire Kaluga oblast: 404 settlements; mean cumulative effective dose 6.3 ± 4.9 mSv
1 2 57 14.1
2 3 83 20.5
3 4 50 12.4
4 5 36 8.9
5 7 38 9.4
7 10 52 12.9
10 15 62 15.3
15 20 20 5.0
20 25 6 1.5
2.3. ESTABLISHMENT AND FEATURES OF THE STUDY COHORTS
Unfortunately for the purpose of this study, it was not possible to establish study cohorts on
the basis of the population of settlements with similar contamination levels. This is due to the
lack of reliable population data on the settlement level. It was thus necessary to resort to the
rayon level, where sufficiently accurate population statistics can be obtained.
To establish the study cohorts, three groups of rayons were formed according to the prevailing
levels of ground contamination:
highly contaminated: Gordeevsky, Zlynkovsky, Klintsovsky, Krasnogorsky,
Novozybkovsky rayons of the Bryansk oblast;
slightly contaminated: Zhizdrinsky, Ulianovsky, Khvastovichsky rayons of the Kaluga
oblast;
control: Baryatino, Babynino, Tarussa rayons of the Kaluga oblast.
The group of highly contaminated rayons includes the five most highly contaminated rayons
of the Bryansk oblast, where the mean density of soil contamination with 137Cs was higher
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than 400 kBq/m2 at the time of the accident. The group of slightly contaminated study rayons
includes three rayons of the Kaluga oblast, where the mean density of soil contamination with
137Cs was 90 - 200 kBq/m2 at the time of the accident. Almost all rayons of the Bryansk and
Kaluga oblasts are contaminated with radionuclides after the Chernobyl accident, but at
substantially different levels. Three rayons of the Kaluga oblast which were contaminated
with less than 25 kBq/m2 at the time of the accident serve as control rayons.
2.3.1. DOSES RECEIVED BY THE STUDY COHORTS
The effective cumulative doses between 1986 and 1995 received by the study cohorts (highly
contaminated, slightly contaminated and control) varies by more than two orders of
magnitude. The actual doses are given in table 2.3.
Table 2.3 Cumulative effective doses and mean cumulative effective doses due to
Chernobyl for 1986-1995 in the study cohorts
RAYONS
Mean
cumulative
effective dose
(mSv) due to
Chernobyl
over 10 years
(1986-1995)
Mean annual
cumulative
effective dose
(mSv) due to
Chernobyl
during 1986-
1995
Cumulative
effective dose
(person Sv)
due to
Chernobyl
1986-1995
Mean annual
population
(in 1 000)
1986-1995
Highly contaminated 22.9 2.29 5 098 222.6
Slightly contaminat. 7.4 0.74 343 46.2
Control 0.35 0.035 15 42.2
2.3.2. DEMOGRAPHIC FEATURES OF THE POPULATION IN THE STUDY AREAS
Demographic data on the age and sex structure of the population of the rayons under study
were contributed by the Oblast Statistics Committee (Oblkomstat) on the basis of the censuses
in 1979 and 1989. Table 2.4 gives the population at both censuses and in 1998.
Table 2.4 Population (in 1 000) in the three groups of rayons under study at the two
censuses (1979 and 1989) and in 1998
RAYONS 1979 1989 1998
Difference
1979-1998
(in % of 1979)
Highly contaminated 243.4 227.7 208.7 - 14.3
Slightly contaminat. 57.4 42.4 38.7 - 32.6
Control 39.9 39.1 47.6 + 19.3
The change in population size clearly exceeds the effect of a change in birth rate. This is also
evident when assessing the demographic structure of the different populations (fig 2.3). The
changes in the study regions must therefore be partly due to migration. Unfortunately, it is
difficult to obtain detailed information on migration on the rayon level, especially where the
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people might have migrated from or to [KOR 03]. Nevertheless, several aspects suggest that a
possible migration effect would not strongly bias the overall results of this study.
Migration may be compulsory or chosen, even if it is an official resettlement of inhabitants of
some highly contaminated areas by the local (oblast) authorities. The compulsory resettlement
concerns only extremely highly contaminated areas and mostly happened fairly shortly after
the accident, before high individual doses had been accumulated. Since any type of official
resettlement took place within the same oblast or even within the same rayon, the population
increase in the control rayons in the Kaluga oblast cannot be due to people officially resettled
from the extremely highly contaminated areas in the Bryansk oblast. Due to much lower
contamination, there was no compulsory resettlement at all in the Kaluga oblast. People
migrating from the slightly contaminated study rayons (which are all located in the Kaluga
oblast) to the control rayons in the Kaluga oblast might account for some of the population
increase in the control rayons [KOR 03]. Their radiation risk, however, is so low (cf. 3.2.) that
it is negligible in view of the remainder of the control cohort.
People may also migrate on their own accord for various reasons not directly linked to the
radiation, i.e. for economic reasons or simply because they have family in other places, for
example in Moscow [KOR 03]. These people would not necessarily be those with the highest
risks. Since this type of migration would have occurred similarly in the highly contaminated
and the slightly contaminated rayons, it would lead to non-differential misclassification.
For the above stated reasons, any migration might lead to a slight underestimation of the risk
in the highly contaminated rayons in the worst case, but would not result in an overestimation
of the risk in the control rayons.
Figure 2.3 illustrates that the sex and age structure of the three groups of rayons under study
are comparable. The most striking feature is the dramatic decrease of the youngest age group
(children 0-4years) between 1989 and 1998.
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Fig 2.3 Demographic structure: share (%) of each 5-year age group in relation to the entire (male &
female) population, the highest age group being 70+
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2.4. TECHNIQUES OF ASCERTAINMENT AND VERIFICATION OF LEUKAEMIA CASES
The algorithm of the collection of leukaemia cases and of the verification of the diagnosis was
elaborated by the staff of the Russian Medical and Dosimetric Registry in Obninsk. It is based
on the cancer care and registration system of the former Soviet Union (fig 2.4).
Fig 2.4 Cancer care and registration system of the former Soviet Union
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The system of cancer care and registration that was in use in the former Soviet Union worked
separately from the general health care system, but was structured analogously. The structure
of this system has been conserved to the present day. The formation is strictly hierarchical,
paralleling the administrative structures from the lowest level of the Uchastok - which exists
only in the medical field – up to the level of the Republic. The resulting registries are
population-based because the entire health care process is tied to the place of residence of the
patient. The health care institutions are responsible for disease prevention and screening,
diagnosis and therapy as well as for the registration of specific diseases.
The basic institution in which cancer patients are diagnosed and treated is the oblast
oncological dispensary (OOD). Here all relevant medical and statistical information is stored
in the archives.
The starting point of the collection and verification process thus is the OOD. Nevertheless, it
sometimes involves medical institutions at the district level (in towns or in the country). This
is due to some peculiarities of the leukaemia diagnosis, treatment and registration process in
Russia, namely that the registration is covered by the OODs, whereas the diagnosis and
treatment of leukaemia patients, as a rule, is performed in specialized haematological
departments, possibly even in other oblasts than the patients‘ residence. Patients might thus
not be in ‚their‘ population-based registry, so that the case has to be ascertained at the
institution in question.
The routine documents for the diagnostic, therapeutic and registration process of solid
cancers, leukaemia and lymphomas which are officially approved by the Ministry of Health
are listed in tables 2.5 and 2.6. They form the basis for the collection of cases and the
verification of diagnoses in this study. Table 2.5 gives the primary documents used in the
Oblast Oncological Dispensary as well as in all in- and out-patient facilities. Further
documents used in (specialized) medical institutions are given in table 2.6.
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Table 2.5 Primary documents involved in the process of leukaemia registration
DOCUMENT TYPE OFFICIALFORM № INSTITUTION
INFORMATION
TRANSMITTED/
RECORDED
1. PRIMARY DOCUMENTS OF THE CANCER REGISTRATION PROCESS
1.1 Notification
of a cancer case diagnosed
for the first time
090/u
all general and specialized
in- and out-patients
departments notify the
cancer registry at the Oblast
Oncological Dispensary
(OOD)
notification of a newly
diagnosed cancer case
1.2 Extract
short extract from the
medical history or the out-
patient card
027-1/u
all medical institutions in
which cancer is diagnosed
and treated notify the cancer
registry at the OOD
notification following
diagnosis & treatment
1.3 Сontrol Card
control card for the follow-up
of cancer patients at the
oncological dispensary
030-5/u the cancer registrationdepartment at the OOD
the Control Card is
established when a new
case is registered and is
then regularly up-dated.
Multiple primaries are
registered on one Control
Card.
No Control Card exists for
DCO-cases, Control Cards
of deceased patients are
removed from the database
1.4 Protocol 027-2/u
all institutions in which
cancer is diagnosed; 2
copies: one copy for the
OOD, the other remains in
the archives of the issuing
institution
reasons for late diagnosis in
case of detection of a
cancer case at an advanced
stage
2. PRIMARY MEDICAL DOCUMENTS
2.1 Out-patient Card
medical card of the out-
patient
025/u all out-patient facilities lifetime out-patient record
2.2 Medical History 003/u all in-patient facilities medical history for eachsingle admission
2.3 Epicrisis
detailed extract from the
medical history
027-2/u all in-patient facilities summary of diagnosis &treatment
3. ADMINISTRATIVE DOCUMENTS
3.1 Certificate of death 106/u
all medical doctors, for
submission to the vital
statistics departments
(ZAGS)
date, cause and place of
death as well as the place of
official registration
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Table 2.6 Other documents consulted in the ascertainment and verification process
DOCUMENT TYPE INSTITUTION INFORMATION
RЕCORDED
1. DOCUMENTS OF CANCER REGISTRATION
1.5 Electronic cancer registry OOD
name, first name, year of birth,
address, diagnosis, date of
registration
1.6 List of initially diagnosed
cancer patients OOD
name, first name, year of birth,
address, diagnosis, date of
registration
1.7 Journal of initially diagnosed
cancer patients
Oncological Cabinet at the
Central Rayon Clinic
name, first name, year of birth,
address, diagnosis, date of
registration
1.8 Journal of deaths of cancer
patients
Oncological Cabinet at the
Central Rayon Clinic
name, first name, year of birth ,
address, diagnosis, date of death
2. MEDICAL DOCUMENTS
2.4 Journal of myelograms &
cytochemical analyses
Clinical – Diagnostic
Laboratories of the Oblast
Clinic (OC) & the
Paediatric Oblast Clinic
(POC)
name, first name, department, date
and results of the analysis
2.5 Journal of biopsies of bone
marrow or lymphatic nodes
Patho-Anatomical
Laboratory of the OC & the
POC
name, first name, department, date
and results of the analysis
2.6 Medical comment consulting out-patientdepartments
diagnosis, state at the moment of
consultation, recommended therapy
of the consulting haematologist
2.7 Protocol of autopsy
Patho-Anatomical
Laboratory of the OC & the
POC
name, first name, department, date
and result of the autopsy
This entire complex of accessible documents in the various medical institutions from the
rayon to the oblast level allowed a complete collection of possible information on the
leukaemia cases. The algorithm that was followed in the data collection is given in table 2.7.
Details of the collection and verification of leukaemia cases are described in the annexe. In
the process of the quality assessment of the data pertaining to every case the information was
recorded in a special form, the Verification Card of the Leukaemia Patient (Annexe 2, figure
A2.1).
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Table 2.7 Process of ascertainment and verification of leukaemia cases
TASKS SOURCES OF INFORMATION
STAGE I
Oblast Oncological Dispensary
Comparison of data entered into the database with
primary data for the following items:
1) correctness and completeness of diagnosis
2) verification of dates
3) agreement between clinical and histological
diagnosis
Search for cases absent in the database (db)
Elimination of unconfirmed cases from the database
Notification of cancer cases (1.1)*
Extract from medical history (1.2)*
Control card (1.3)*
Electronic database of the OOD (1.5)*
Journal of deceased cancer patients (1.7)*
Out-patient Card (2.1)*
STAGE II
Oblast Clinic
Paediatric Oblast Clinic
Archives and Registration Office
Verification of recorded diagnoses
Search for new cases
Elimination of unconfirmed diagnoses
Out-patient Card (2.1)*
Medical History (2.2)*
Epicrisis (2.3)*
Histological Archives of the Clinical-Diagnostic and
Patho-Anatomical laboratory at the OC & POC (2.4, 2.5,
2.6)*
STAGE III
Central Rayon Clinic
Archives and Registration Office
Comparison of data entered into the database of the
oncological dispensary with primary data from the rayon
Verification of recorded diagnosis leukaemia
Search for cases absent in the database
Elimination of unconfirmed diagnoses
Out-patient Card (2.1.)*
Medical History (2.2.)*
Journal of the Oncological Cabinet (1.7, 1.8)*
Archive of the ZAGS (3.1)*
* the figures in brackets refer to tables 2.5 and 2.6.
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2.5. RESULTS OF ASCERTAINMENT AND VERIFICATION
As a result of the consultation of the official and local registration and medical documents,
patients formerly not registered were taken into account. At the same time, cases had to be
excluded from the analysis because the diagnosis could not be confirmed. These movements
in the primary database and the finally resulting database are documented in table 2.8.
2.5.1. REGIONAL DIFFERENCES
The results of the ascertainment and verification of leukaemia cases in the different study
regions is presented in table 2.8.
Table 2.8 Results of ascertainment and verification of leukaemia cases in the different study regions
CASES
Ascertainment Verification
Added Excluded
GROUPS OF RAYONS
UNDER STUDY
OOD
Data-
base
No %
Interim
total
No %
Final
Project
Database
Highly contaminated 255 12 4.7 267 20 7.5 247
Slightly contaminat. 41 6 14.6 47 2 4.2 45
Control 35 18 51.4 53 12 22.6 41
TOTAL 331 36 10.9 367 34 9.3 333
331 leukaemia cases had been registered in the original database at the oblast oncological
dispensary for the study rayons during the years 1980 – 1998. On scrutinizing the documents
of other haematological disorders and cancers as well as of institutions other than those
located directly in the study areas, 36 validated cases were added (10.9% of the cases
originally registered at the OODs). It should be pointed out that the highest percentage of
cases revealed through active registration during this project in relation to the originally
registered cases in the database of the Oblast Oncological Dispensary occurred in the control
rayons.
The further verification of diagnoses led to the exclusion of 34 cases (9.3% of the new total),
leaving 333 cases in the final analysis.
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2.5.2. SOURCES OF AND GROUNDS FOR INCLUSION AND REASONS FOR EXCLUSION OF CASES
A detailed description of the sources of the cases added to the database after case
ascertainment and the grounds for their inclusion are given in table 2.9.
Table 2.9 Sources of and grounds for inclusion of leukaemia cases in the database
CASES
No %TOTAL  OF  CASES  INCLUDED
36 100
Source and grounds for inclusion
OOD
date of diagnosis changed
discovered in other than the study rayons
revealed in the archives of out-patient cards
revealed in the main electronic database of all tumours with:
stomach cancer
lymphoma
lymphomatoid granulomatosis
21
4
2
10
5
2
2
1
58.4
11.1
5.6
27.8
13.9
Oblast Clinic
haematological department
11 30.6
Clinical-Diagnostic Laboratory
journal of myelograms (2.4)*
2 5.5
Oncological Cabinet at the Central Rayon Clinic
journal of initially diagnosed cancer patients (1.7)*
2 5.5
* the figures in brackets refer to tables 2.5 and 2.6
Nearly 60% of the 36 cases added to the database were discovered in Oblast Oncological
Dispensaries – either of the study regions or, in two cases, of neighbouring oblasts. Ten cases
of those that were found in the study area had simply not been reported earlier, but were
diagnosed and registered correctly in the out-patient cards, whereas nine cases had not been
included in the database for faulty information: in four cases the date of diagnosis was
incorrect, and in five cases the diagnosis itself proved to be wrong.
Over 40% (fifteen cases) had not been registered at the Oblast Oncological Dispensary at all.
They were discovered by searching medical records and archives of other general and
specialized medical institutions of the oblast.
An overview of the results of case ascertainment and data verification together with the
reasons for the exclusion of cases is presented in table 2.10.
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Table 2.10 Results of case ascertainment and data verification together with reasons for the
exclusion of cases
CASESCHANGES  IN  THE  DATABASE No %
Number of cases in the database of the OOD 331 100
Added cases 36 10,9
A
SC
E
R
T
A
IN
-
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E
N
T
Total 367 100
Rejected: 34 9.3
due to mistakes of diagnosis 25 6.8
due to technical errors (wrong address, duplication of data,
diagnosis established before 1980 or after 1998)
9 2.4
Accepted cases 333 100
Quality of data improved: 219 65.8
type of leukaemia recorded more precisely 84 25.2
date of birth recorded more precisely 65 19.5
V
E
R
IF
IC
A
T
IO
N
date of diagnosis recorded more precisely 70 21.0
The database resulting after the inclusion of the 36 cases stated in table 2.9 consisted of 367
cases. Each case was carefully verified which led to the subsequent exclusion of 34 cases.
Obviously it was not possible to verify all information in the database - neither for all areas
under study nor for all times, especially not for the earlier years for which parts of the
documents are not in the archives. The same applies to the bone marrow smears, which have a
limited conservation period of five years. A detailed description of the various reasons for
exclusion is presented in table 2.11.
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Table 2.11 Reasons for exclusion of leukaemia cases due to mistakes
CASES
No %TOTAL  NUMBER  OF  CASES  EXCLUDED
34 100
due to wrong diagnoses 25 73.5
Diagnosis in the database Correct diagnosis
Chronic lympholeukaemia (204.1)
Chronic erythroleukaemia (207.1)
Chronic leukaemia (208.1)
Non-Hodgkin’s lymphoma (200.1)
Multiple myeloma (203.0)
Lymphogranulomatosis (201)
Symptomatic erythraemia (289.0)
Aplastic anaemia (284)
8
7
1
1
1
47.1
2.9
2.9
Acute leukaemia (208.0)
Anaemia of uncertain aetiology (285.0)
Megaloblastic anaemia (281.0)
Death before diagnosis, no autopsy (798.2)
3
1
2
17.7
Leukaemia (208.9) Lymphatic node metastasis (196.9) 1 2.9
due to technical errors 9 26.5
Wrong address
Duplication of data
Diagnosis already established in a region not included in the study
Diagnosis established before 1980 or after 1998
3
2
1
3
8.8
6.0
2.9
8.8
Most (73.5%) of the cases that had to be excluded from the database had to be discarded due
to wrong diagnoses. The most problematic diagnoses were chronic leukaemia, especially
CLL, half of which (8 cases) had been misdiagnosed as Non-Hodgkin’s lymphoma. Seven
alleged cases of CLL were in fact multiple myeloma but had been miscoded by the technician
at the cancer registry.
A detailed description of the verification of diagnoses at all stages is included in Annexe 2.
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2.6. TYPE OF STUDY AND STATISTICAL METHODS
The study is designed as a prospective population-based cohort study with a control group
(‘prospective’ in that the exposure – in this case the ground contamination – is measured
before the disease onset). In view of the negligible radiation risks of the cohort from the
slightly contaminated rayons (cf. 3.2), these study rayons are pooled with the control rayons
for the analysis to form the combined control rayons (CCR) and thus increase the power of
the study.
A descriptive analysis is performed on all the cases:
In a regional analysis, the absolute number of cases as well as the crude and age- and sex-
standardized (world standard) rates in the highly contaminated rayons (HCR) are compared to
those of the combined control rayons (CCR). 95% Confidence Intervals according to Poisson
are given for the crude rates and the χ²-test is performed to test for homogeneity of the
standardized rates. Age-specific rates over the entire study period are given for the
contaminated and the control rayons together with 95% Confidence Intervals according to
Poisson.
In a temporal analysis, three study periods (cf. 2.1) are introduced. The resulting increase in
power then allows a separate analysis for children (0-14 years) and adults, in which the
standardized incidence rates for the three study periods in the contaminated and the control
rayons are compared.
When discussing the possibility of detecting a radiation effect in the study rayons, 95%
confidence intervals are given for the 703 cases expected in the study cohort over the entire
lifetime. They are calculated on the basis of a standard distribution which provides a good
approximation of the Poisson distribution for larger numbers.
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3. RESULTS
All cases that occurred in the study areas between 1980 and 1998 – altogether 333 - were
taken into the analysis.
3.1. ANALYSIS OF DATA QUALITY
3.1.1. DISTRIBUTION OF CASES BY PERIOD
Table 3.1 shows the distribution of the cases by region and three time periods.
Table 3.1 Distribution of cases by period
1980-98 1980-86 1987-92 1993-98RAYONS
No % No % No % No %
Highly cont. 247 100 79 32,0 77 31,2 91 36,8
Slightly cont. 45 100 14 31,1 6 13,3 25 55,6
Control 41 100 11 26,8 13 31,7 17 41,5
Total 333 104 96 133
The cases are evenly distributed only in the highly contaminated rayons. There is an increase
in the slightly contaminated and control rayons between the second and the third period by a
factor of 2.2 for both types of rayons together. Interestingly this reflects roughly the
magnitude of the actual increase in these rayons (cf. the standardized incidence rates, chapter
3.5, fig 3.6). Furthermore, it is improbable that an increase in reporting due to elevated
awareness after the Chernobyl accident should occur between the second and the third period.
Such an increase, if any, would have been expected in the second period in comparison to the
pre-accident period (cf. chapter 2.5.1, table 2.8).
3.1.2. DISTRIBUTION OF CASES BY AGE
The distribution of cases by age in the different regions is given in table 3.2.
Table 3.2 Distribution of cases by age
1980-98 1980-86 1987-92 1993-98
RAYONS age
0-14
age
15+
age
0-14
age
15+
age
0-14
age
15+
age
0-14
age
15+
Highly cont. 27 220 14 65 5 72 8 83
Slightly cont. 3 42 1 13 0 6 2 23
Control 5 36 0 11 4 9 1 16
Total 35 298 15 89 9 87 11 122
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Over the entire period and in all the cohorts, 10.5% of the cases occurred in children (0-14
years), 89.5% in adolescents and adults. Due to the very small number of cases in children in
the separate cells, a large variation of the corresponding percentages can be expected. The
variation diminishes when looking at the different study cohorts over the entire period. The
overall pattern is similar to that in other countries [CIN 92, 97]. However, the study rayons
are rural areas and it cannot be ruled out that there is an underdetection (rather than an
underregistration!) in the elder age groups. If anything, such a possible underdetection might
be expected to increase with the deterioration of the public health care system in the 1990s. It
must be emphasised that there is no indication of this being a major problem in this study.
3.1.3 DISTRIBUTION OF CASES BY DIAGNOSIS
The pattern of the different types of leukaemia in the study and control regions in the different
periods is demonstrated in figs. 3.1 – 3.3. The corresponding data are given in tables A2.2-
A2.5 in ANNEXE 2.
The distribution of leukaemia subtypes shows similar patterns regardless of the period, but the
share of leukaemia not otherwise specified (ICD 9 208.0, 208.1, 208.9) decreases in the later
years.
In children (fig. 3.1), most cases are acute lymphoblast leukaemia, as is typical in the
remainder of Russia and the World [ALE 88, CIN 97]. Unfortunately no prevalence of
different phenotypes or the Philadelphia chromosome (Ph+ or Ph-) in acute lymphoid
leukaemia can be given because cytogenetic analysis is scarcely performed. It may be
assumed that some of the more aggressive cases were Ph+ as this phenotype is known to be
especially resistant to therapy [SCH 98, UCK 99]. One of the 35 cases detected in children
was found to be chronic myeloid leukaemia in an eight-year-old boy. CML is an extremely
rare disease in children; nevertheless, in this case the diagnosis was undoubtedly correct [FRE
98]. As the atypically high percentage (2.86%) of CML in children in the study regions is due
to only this one case it can clearly not be seen as an overdispersion.
In adults (fig 3.2), the pattern of distribution of different leukaemia subtypes is typical of all
periods of the study and conforms to the pattern in the remainder of Russia and the World
[CIN 97]. 38.8% of all cases in adults were acute leukaemia, 55.2% chronic forms. In 6% of
the cases, the form could not be established retrospectively.
The distribution of the different cytological types of leukaemia depends on the age (figs. 3.1,
3.2, ANNEXE 2 table A2.2-A2.3). Neither the distribution of the acute nor of the chronic
forms (ANNEXE 2 table A2.5) differ from Russian and international data of the recent years
[CIN 97]. Most (85%) of the cases of acute leukaemia in children were lymphoid leukaemia,
in adults their share was 37.8% of the acute forms. Among the cases of chronic leukaemia in
adults, CML accounted for 34% and CLL for 56%, which is totally in line with international
experience [FAJ 80, SCH 93, KRO 95].
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Fig 3.1 Different forms of leukaemia in children in the three time periods
87-92
Fig 3.2 Different forms of leukaemia in adults in the three time periods
highly contaminated
slightly contaminated
control
Fig 3.3 Different forms of leukaemia in the different rayons under study in 1980-1998
ALL 204.0
AML 205.0
AUL 208.0
ALNOS 208.0
CLL 204.1
CML 205.1
CLNOS 208.1
LNOS 208.9
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93-98
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In recent years scientists came up with the idea that some forms of CLL might be inducible by
radiation, especially leukaemia stemming from large granular lymphocytes of the phenotype
of natural killer cells [GLU 01, IMA 01, LAM 98, LOU 98, IMA 90]. Unfortunately no cases
with cells typed as large granulating cells or as natural killer cells were found. Although these
cells may be identified by morphological criteria from routinely stained smears, this
information is not available from most Rayon or even Oblast Clinics.
The only aspect that draws attention is the fact that the cases of chronic leukaemia are nearly
evenly distributed among CML and CLL in the contaminated rayons of the Kaluga oblast
whereas usually the incidence of CLL in Russia is 1.5-3 times higher than that of CML. So far
there is no explanation for this overdispersion of CML.
All in all, there is no indication of poor data quality in respect of the diagnostic accuracy after
the verification of diagnoses in the framework of this study.
3.2. CUMULATIVE ATTRIBUTABLE RISKS OF LEUKAEMIA
The attributable risk indicates the percentage of the cases that may be attributed to the
influence of a certain causative factor during a defined time period. The cumulative
attributable risks of leukaemia due to the radiation after the Chernobyl accident among the
population of the contaminated rayons of the Bryansk and Kaluga oblasts are given in table
3.3. The cumulative risks were calculated using the prognostic UNSCEAR-model [UNS 94]
for the time after the latent period, beginning from 1989. The total life-expectancy was
assumed to be 90 years.
Table 3.3 Estimation of cumulative attributable risks of leukaemia [KAI 02]
CUMULATIVE ATTRIBUTABLE RISKS OF LEUKAEMIA (ENTIRE POPULATION)
1989-1994 lifetime expectedAFFECTED
RAYONS
calculated
baseline
(cases)
radiation-
related
(cases)
attributable
(%)
baseline
(cases)
radiation-
related
(cases)
attributable
(%)
Gordeevsky 4.40 0.78 15.1 48.3 2.07 4.1
Zlynkovsky 4.49 0.91 16.9 50.5 2.46 4.6
Klintsovsky 32.1 2.42 7.0 344.0 6.21 1.8
Krasnogorsky 6.01 1.68 21.8 64.2 4.32 6.3
Novozybkovsky 18.49 3.45 15.7 196.5 8.86 4.3
Highly
contaminated 65.49 9.24 12.4 703.5 23.92 3.3
Zhizdrinsky 4.25 0.17 3.8 49.2 0.46 0.9
Ulianovsky 3.41 0.2 5.5 41.9 0.59 1.4
Khvastovichsky 5.07 0.25 4.7 56.4 0.68 1.2
Slightly
contaminated 12.73 0.62 4.6 147.5 1.73 1.2
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The radiation-related attributable risks of leukaemia for the years from 1989 to 1994 are
12.4% in the highly contaminated rayons and 4.6% in the slightly contaminated rayons. As
the radiation-induced risk of leukaemia decreases with time following the exposure, the
lifetime attributable risk is approximately 3 to 4 times lower than the attributable risk for the
period 1989-1994. Estimates show that about 75% of all radiation-induced lifetime cases
would occur within the 15 years after the latent period, i.e. between 1989 and 2003.
3.3. ANNUAL NUMBER OF CASES AND STANDARDIZED INCIDENCE RATES –
A REGIONAL COMPARISON
The cumulative attributable risk in the population of the three contaminated Kaluga rayons is
very small (table 3.3). For further analysis, these three rayons will be combined with the three
control rayons of the Kaluga oblast. They will thus form a larger control group (combined
control rayons, CCR) for a powerful statistical analysis in relation to the Bryansk study
rayons (highly contaminated rayons, HCR).
To date, it has not been proved that CLL is induced by radiation. The following analyses were
therefore performed both for all leukaemia and for all leukaemia excluding CLL.
The number of leukaemia cases between 1980 and 1998 among males and females for all
leukaemia and for all leukaemia excluding CLL are presented in fig 3.4 for the highly
contaminated (a-b) and the combined control rayons (c-d). The mean annual number of all
leukaemia in the highly contaminated rayons is 13, ranging from 6-20; in the combined
control rayons it is 4.53, ranging from 0-11. This difference in annual incidence is not
significant when considering the difference in population size and age and sex structure, as
can be seen from the standardized incidence rates.
Leukaemia incidence rates differ in the various age groups and between the sexes. This
implies that the age and sex distribution in a population influences the crude incidence rates.
In order to assess the incidence rates of different times and regions it is thus necessary to
adjust for the composition of the population, i.e. to directly standardize the rates in order to
make them comparable.
Crude and standardized (world standard) incidence rates per 100 000 persons between 1980
and 1998 are given in fig 3.5 for the highly contaminated rayons and in fig 3.6 for the
combined control rayons. The rates for all leukaemia (a-b) and for all leukaemia excluding
CLL (c-d) are given for males and females separately. The crude rates are given separately
with the corresponding 95%-CI’s; no significant fluctuations is observed between the years.
The regression line indicates the trend of the standardized rates over the entire period.
It is remarkable that the standardized rates are rather instable in their relation to the crude
rates and this might lead one to assume that the population in the study areas is extremely
unstable from one year to the next. This is, however, not the case. The effect is due to the
small number of cases in each year and the fact that they are distributed very inhomogenously
between the various age-groups.
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The mean morbidity in males in the contaminated rayons (all leukaemia: 6.2/100 000 [95%CI
5.1; 7.4] per year, all leukaemia excluding CLL: 4.2/100 000 [95%CI 3.3; 5.2] per year) is
comparable to that in females in the contaminated rayons (all leukaemia: 5.8/100 000 [95%CI
4.9; 6.9] per year, all leukaemia excluding CLL: 4.5/100 000 [95%CI 3.7; 5.5] per year, the
difference being non-significant: p-value of two-sample test for binomial proportions [BIN
02] 0.61 and 0.70 respectively). The same is true for the combined control rayons (all
leukaemia among males: 5.4/100 000 [95%CI 3.9; 7.4] per year, all leukaemia excluding
CLL: 3.3/100 000 [95%CI 2.1; 4.9] per year; all leukaemia among females: 5.1/100 000
[95%CI 3.7; 6.7] per year, all leukaemia excluding CLL among females: 3.4/100 000 [95%CI
2.3; 4.9] per year, the difference being non-significant: p-value of two-sample test for
binomial proportions 0.74 and 0.87 respectively).
The leukaemia rates and their secular trends are comparable in the highly contaminated
rayons and in the combined control rayons: there is a very small increase over time and this is
slightly more marked among females than among males both for all leukaemia excluding
CLL and for CLL alone.
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c) All leukaemias / combined control rayons
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d) All leukaemia excluding CLL / combined control rayons
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Fig 3.4 Leukaemia cases over the entire study period (1980-1998)
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a) All leukaemia / males
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b) All leukaemia / females
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c) All leukaemia excluding CLL / males
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Fig 3.5 Crude and standardized (world standard) incidence rates (per 100 000) in the highly
contaminated rayons. Vertical bars indicate 95% CI’s for the crude rates according to Poisson;
the regression line is calculated for the standardized rates
RESULTS 38
a) All leukaemia / males
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b) All leukaemia / females
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c) All leukaemia excluding CLL / males
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Fig 3.6 Crude and standardized (world standard) incidence rates (per 100 000) in the combined
control rayons. Vertical bars indicate 95% CI’s for the crude rates according to Poisson; the
regression line is calculated for the standardized rates
d) All leukaemia excluding CLL / females
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3.4. STANDARDIZED INCIDENCE RATES – A TEMPORAL COMPARISON
In fig 3.7, the standardized (world standard) incidence rates are given for each of the three
periods for all leukaemia and for all leukaemia excluding CLL. A comparison of the
standardized rates for adults in the highly contaminated and the combined control rayons
shows – both for all leukaemia and for all leukaemia excluding CLL - that the incidence rates
are higher in the highly contaminated rayons in the earlier periods. There is a slight increase
in incidence rates for both groups of rayons mainly in the third period. However, this increase
is more marked in the combined control rayons, so that the incidence rates for the third period
are similar in the combined control rayons and in the highly contaminated rayons.
a) All leukaemia / males & females
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b) All leukaemia excluding CLL / males & females
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Fig 3.7 Standardized (world standard) leukaemia incidence rates (per 100 000) over the three study
periods
The standardized leukaemia incidence rates for children (0-14 years) shown in fig 3.8 are
substantially higher in the highly contaminated rayons in the pre-accident period, but drop
below the rates of the combined control rayons in the early and the later post-accident period -
the rates in the later post accident period are practically identical. This effect is due both to a
decrease in the rates in the contaminated rayons and an increase in the rates in the combined
control rayons.
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Fig 3.8 Standardized (world standard) leukaemia incidence rates (per 100 000) in children (boys and
girls) over the three study periods. The figures indicate the number of cases that the rates are
based on (cf table 3.2.)
The results of the comparison of standardized incidence rates in the highly contaminated
rayons of the Bryansk oblast and the combined control rayons of the Kaluga oblast show no
statistically significant difference, neither for all leukaemia, nor for all leukaemia excluding
CLL. There is a slightly increasing secular trend in the standardized incidence rates in adults
of all leukaemia as well as of CLL. This increase is more marked in the combined control
rayons than in the highly contaminated rayons. The standardized incidence rates in children
have clearly increased over time in the combined control rayons, but have decreased in the
highly contaminated rayons.
3.5. AGE-SPECIFIC INCIDENCE RATES
An important aspect in the description of leukaemia incidence is the specific incidence in the
different age groups. Age-specific incidence rates of all leukaemia and all leukaemia
excluding CLL in 5-year age groups are given in fig 3.9 for males (a, c) and females (b, d) in
the highly contaminated and the combined control rayons. The age-specific incidence rates
were calculated over the entire study period (1980–1998) in order to increase statistical
power. Table 3.4 gives the age-specific incidence rates with the corresponding 95% CI’s.
The age-specific incidence rates in children are higher for boys in the combined control
rayons than in the contaminated rayons, but the opposite is true for the incidence in girls. This
difference is not significant at the 95% level of confidence. In adults (apart from the age
group 35-44), there is a tendency towards higher rates in the contaminated rayons in
comparison with the combined control rayons for all leukaemia as well as for all leukaemia
excluding CLL. This tendency is also not significant.
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a) All leukaemia / males
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b) All leukaemia / females
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c) All leukaemia excluding CLL / males
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d) All leukaemia excluding CLL / females
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Fig 3.9 Age-specific incidence rates (per 100 000) over the entire study period (1980-1998). Vertical
bars indicate 95% CI’s according to Poisson
Table 3.4 Age-specific incidence rates (per 100 000) with 95% CI’s according to Poisson over the entire study period (1980-1998)
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4. DISCUSSION
4.1. COMPLETENESS AND QUALITY OF THE DATA
The initial database at the local cancer registry consisted of 331 routinely registered
leukaemia cases for the years 1980 to 1998 in the rayons under study. The active search for
cases previously diagnosed but not registered added 36 cases to the project data base. The
search was conducted at all medical and administrative institutions where information on
patients with leukaemia might be found. It can therefore be assumed that all cases diagnosed
between 1980 and 1998 in the rayons under study were finally included in the project data
base.
In spite of this, the possibility that not all patients having leukaemia were diagnosed as such
cannot be dismissed. This is especially true for the older age-groups in rural regions.
However, there is no indication that the extent of underdetection varied during the study
period. If anything, the level of detection might have been expected to improve with an
improving health care system in the late 1980s and to subsequently deteriorate during the
1990s with the crisis of the health care system after the disintegration of the Soviet Union.
This would also apply especially to the elderly, who often cannot afford the previously cost-
free public health service. A general under-registration of cancer incidence rates in Russia for
the age-groups 70+ has been reported [SHK 99], and is highly likely to have also occurred in
the present study. Only the order of magnitude remains speculative. Such an under-detection
of cases on a stable level, however, is not important in relation to the assessment of a possible
radiation effect, neither in the regional nor in the temporal analyses.
Furthermore, varying levels of completeness of cancer registration in Russia in the 1980s and
1990s due to changing coding practises of death certificates have been observed [SHK 99].
This effect would only concern cases added to the data base by the evidence of the death
certificate only (DCO cases). Due to the extensive follow-up on every case included, there are
no DCO cases in the present study.
In order to optimize the quality of the data, all information included in the project data base
was verified directly at the responsible medical and administrative institutions. This led to the
exclusion of 34 cases: in 18 ‘non-cases’ the initial diagnosis proved to be wrong, whereas 16
‘non-cases’ were due to technical errors (miscoding of a diagnosis other than leukaemia as
leukaemia, wrong addresses, dates, etc.). The fact that only 18 cases (4.9%) had to be
excluded from the project data base due to misdiagnosing testifies to the high level of
accuracy and precision of the initial diagnoses. This is in line with the experience of an
international haematologic panel reviewing leukaemia cases from the Ukraine, where the
‘haematologists and haemopathologists on the panel were in agreement with one another and
with the previously reported diagnoses and classifications of about 90% of the cases of acute
and chronic leukaemia in the study’ [DYA 02]. The accuracy in this study was supported by
the fact that ICD 9 with its exhaustive and mutually exclusive categories had been initially
used as opposed to being attributed to the cases in the course of the study.
DISCUSSION 45
The frequency distributions of the different types of leukaemia in the different study rayons
and periods are homogeneous, as are the age and sex distributions. An external comparison
furthermore shows these parameters to be in line with international experience [SEE 03, CIN
97]. These findings indicate high internal and external validity of the data.
It is remarkable but most probably purely coincidental that the order of magnitude of false-
negative cases (36 cases added to the project data base through active detection,
corresponding to 10.9% of the 331 cases in the initial database) and of false-positive cases (34
cases omitted, corresponding to 10.3% of the initial cases) is the same. This implies that the a
priori error that would have occurred in an analysis previous to the extensive data-check is
equal to the a posteriori error and must, in any case, be smaller than 10% of the number of
cases.
4.2. CONTINUITY OF THE DOCUMENTATION AND POSSIBLE BIASES
The absence of abrupt, statistically significant changes in incidence rates over time or
between the groups of study rayons points towards the continuity of the documentation of the
cases. It has been suggested that fear in the population and increased awareness among
medical doctors might result in an expectation or a detection bias. Both biases would lead to
elevated incidence rates directly after the accident and a subsequent decrease. In the case of
an expectation bias the incidence rates would simply return to the pre-accident level. In the
case of a detection bias the rates would fall below the pre-accident rates after the initial
increase before returning to the actual level. There is no indication of either an expectation or
a detection bias in this study.
A further source of a possible bias is the migration of the population from the highly
contaminated to the control regions, leading to a misclassification of exposed individuals.
Demographic data on the age and sex structure of the population of the rayons under study
were contributed by the Oblast Statistics Committee (Oblkomstat) on the basis of the censuses
in 1979 and 1989. The change in population size clearly exceeds the effect of a change in
birth rate. This is also evident when assessing the demographic structure of the different
populations. The changes in the study regions must therefore be partly due to migration.
Unfortunately, it is difficult to obtain detailed information on migration on the rayon level,
especially where the people might have migrated from or to [KOR 03]. Nevertheless, several
aspects suggest that a possible migration effect would not strongly bias the overall results of
this study:
Migration may be compulsory or chosen, even if it is an official resettlement of inhabitants of
some highly contaminated areas by the local (oblast) authorities. The compulsory resettlement
concerns only extremely highly contaminated areas and mostly happened fairly shortly after
the accident, before high individual doses had been accumulated. Since any type of official
resettlement took place within the same oblast or even within the same rayon, the population
increase in the control rayons in the Kaluga oblast cannot be due to people officially resettled
from the extremely highly contaminated areas in the Bryansk oblast. Due to much lower
contamination, there was no compulsory resettlement at all in the Kaluga oblast. People
migrating from the slightly contaminated study rayons (which are all located in the Kaluga
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oblast) to the control rayons in the Kaluga oblast might account for some of the population
increase in the control rayons [KOR 03]. Their radiation risk, however, is so low (cf. 3.2.) that
it is negligible in view of the remainder of the control cohort.
People may also migrate on their own accord for various reasons not directly linked to the
radiation, i.e. for economic reasons or simply because they have family in other places, for
example in Moscow [KOR 03]. These people would not necessarily be those with the highest
risks. Since this type of migration would have occurred similarly in the highly contaminated
and the slightly contaminated rayons, it would lead to non-differential misclassification.
For the above stated reasons, any migration might lead to a slight underestimation of the risk
in the highly contaminated rayons in the worst case, but would not result in an overestimation
of the risk in the control rayons.
4.3. STRENGTHS AND LIMITATIONS OF THE STUDY
The strengths of the present study are the completeness and the outstanding quality of the
data: the 333 cases in the final project data base must be considered as the complete number
of cases diagnosed in the study rayons between 1980 and 1998 and the diagnoses can be seen
as incontestable. The results of the analyses thus give an accurate picture of the leukaemia
incidence rates in the study rayons and periods, which allows a realistic assessment of a
possible effect of the radiation released from the Chernobyl Nuclear Power Plant in 1986.
The study cohorts were formed according to the official mean annual effective dose they have
been subjected to due to the Chernobyl accident in addition to their average annual dose
(mainly natural and medical exposure) of about 2.4 mSv. In the years 1986 to 1995, this
additional average annual dose amounted to 2.29 mSv in the highly contaminated rayons, to
0.74 mSv in the slightly contaminated rayons and to 0.035 mSv in the control rayons. Joining
the population of the slightly contaminated rayons and of the control rayons to form the
combined control cohort results in higher statistical power. This is possible without the loss of
power in the risk group, for the cumulative attributable risks at 0.74 mSv are negligible in
view of the size of the study cohort (cf 3.2).
The study does not allow the estimation of risk coefficients because no individual dosimetry
can be provided. Mean doses are computed for the inhabitants of settlements, so that the dose
range would be wide when estimating the dose for an actual individual from this information.
The computation of risk coefficients would require individual dosimetry and a sufficient
control of confounding factors (such as exposure to other risk factors) in a cohort or
preferably even a case-control study.
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4.4. ATTRIBUTABLE RISKS OF LEUKAEMIA IN THE STUDY COHORT AND THEIR
DETECTION
The attributable lifetime risk of leukaemia in the population of the highly contaminated
rayons is estimated to be 24 cases, based on the risk factors from the Life Span Study of the
Japanese cohort. These cases are assumed to occur in addition to a calculated baseline
estimate (without the radiation factor) of 703 cases, adding up to a total of 727 cases
(including the assumed radiation factor). When calculating the 95% confidence interval
(95%CI 651; 755) it becomes clear that such an influence, even if present, would not be
statistically detectable. This is all the more true for the smaller numbers of radiation-related
(9.4) and baseline (64) cases estimated for the years 1989-1994 in the same cohort (95%CI
48.74; 80.25) [SAC 92].
4.5. RESULTS OF THIS STUDY IN COMPARISON TO OTHER EXPOSED COHORTS
An increase of MDS after the Chernobyl accident, as postulated by some Eastern scientists
[IVA 97], is highly unlikely although MDS is thought to be inducible by ionizing radiation
[AUL 98, NIS 01]. However, there is no large-scale experience or estimation of risk co-
efficients, for example from Japan, as MDS had not yet been defined as such. The risk co-
efficients for acute leukaemia from the Japanese studies must thus be seen as an integral
measure of the risks of MDS and acute leukaemia. In this study MDS is not included mainly
because the quality of diagnosis could not be assured, especially for the early years.
Nevertheless, it may be assumed that a dramatic increase in MDS would have been noticed,
as 25%-40% of MDS turn into acute leukaemia in the course of the disease [YOS 96]. This
would have reflected in the present analysis.
4.5.1. CHILDREN
Leukaemia is a rare disease in childhood: in this study, only 35 cases occurred between 1980
and 1998 in the children (0-14 years) of the study cohort (1.84 cases per year). Their
distribution over the years and the study periods leads to very small numbers of cases on
which the individual incidence rates are calculated. This implies that the power of the
statistical analysis is very low. Nevertheless, the absence of an increase in the years after the
Chernobyl accident or of elevated rates in the contaminated versus the control rayons
indicates the absence of a considerable radiation effect in the studied children.
These findings are in line with the findings of studies of similar methodology and quality of
larger childhood populations in the contaminated areas of Belarus, Russia, and the Ukraine
[BEC 02, GAP 01b, IVA 96]. Even a study on the subgroup of infants, who seem to be
especially radio-sensitive [STE 56], could not detect elevated incidence rates for Belarus
[IVA 98]. It therefore seems highly unlikely that the increase in infant leukaemia reported for
Greece [PET 96] is due to radiation, as the contamination in Greece was lower than in Belarus
by a factor of more than 10. This is also true for the average doses in Germany, where even in
the more highly contaminated southern parts the doses remained well below those in Belarus
or the highly contaminated Russian study regions (cf. tab. 4.1).
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No detectable increase due to the radiation after the Chernobyl accident has been reported by
the European Childhood Leukaemia-Lymphoma Study (ECLIS), which compiles data from
36 cancer registries of 23 countries. The authors observe ‘a slight increase in the incidence of
childhood leukaemia in Europe’ but also find that ‘the overall geographical pattern of change
bears no relation to estimated exposure to radiation resulting from the accident’ [PAR 96].
This supports the notion that the lack of a dose-effect relationship cannot be dismissed in
epidemiologic reasoning.
4.5.2 ADULTS
There is no increase in leukaemia incidence rates in the post-accident periods in comparison
to the pre-accident period. Moreover, the incidence rates in the contaminated rayons do not
differ from those in the control rayons. Both are true for all leukaemia as well as for all
leukaemia excluding CLL and no difference has been observed between the sexes. The age-
specific incidence rates show no remarkable features apart from surprisingly low rates for the
older age-groups (cf. 4.1).
These findings are in line with data from other cancer registries covering the most highly
contaminated regions of the Commonwealth of Independent States [GAP 01a, PRI 95], even
if the completeness and quality of the data might vary.
Some regions of the world such as Kerala, India, and Yangjiang, China, are known for their
high natural background radiation. These two regions are populated by about 100 000 persons
each. The total size of these two populations is comparable to that of the highly contaminated
study rayons (222 000) but the mean doses after Chernobyl were much lower (between 1986
and 1995 about 2.29 mSv plus 2.4 mSv from natural background and medical exposure,
altogether about 4.7 mSv per year). Cancer incidence rates and mortality in the populations
continuously exposed to high background radiation (10-100 mSv per year [TUB 00]) have
been monitored for years. There is no indication of an elevated cancer incidence rate or
mortality in either of the regions [TAO 00, NAI 99]. Some authors postulate an adaptive
response induced by chronic exposure to natural background radiation [GHI 02].
Nevertheless, a detection of elevated cancer incidence rates even in the populations more
highly exposed due to the Chernobyl accident would be surprising in view of the cancer rates
in the populations exposed to high natural background radiation.
No increase of cancer risks has so far actually been observed at doses below 200 mSv in
epidemiological studies on the level of the general population. Cases that may be assumed to
occur when extrapolating on the grounds of risk factors derived from higher doses and dose
rates are therefore referred to as virtual cases [TUB 00] or hypothetical risks [BFS 03].
One possible explanation for this phenomenon is the fact that the calculation of the risk
coefficients from the Life Span Study is based on comparatively high doses at a high dose
rate. Yet not only the doses, but also the dose rates, are much lower in the studies in question
than in Japan. For low Linear Energy Transfer (LET) radiations ‘it is evident that theoretical
considerations, experimental results in animals and other biological organisms, and even
some limited human experience suggest that cancer induction at low doses and low dose rates
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should be less than that observed after high doses and dose rates’. For this reason the
International Commission on Radiological Protection (ICRP) has introduced a Dose and Dose
Rate Effectiveness Factor (DDREF) [ICRP 90].
Another possible explanation is the choice of the model used for the calculation of risks at
low doses. The shape of the dose-effect curve at doses below 200 mSv is disputable and may
be anything from a linear function without a threshold or a linear-quadratic to a quadratic
function. The conservative linear no-threshold approach is used in radiation-protection, where
it is vital not to underestimate the risks. The resulting risk coefficients at low doses, however,
may actually be higher than the real risks [TUB 00].
4.6. PUTTING THE RISK IN PERSPECTIVE – A COMPARISON WITH OTHER RISK FACTORS
At this stage it seems important to compare the mean annual effective dose to the population
in the contaminated areas of Russia after the Chernobyl accident with the doses due to other
sources of ionizing radiation (table 4.1)
Tab 4.1 Doses due to various sources of ionizing radiation [BFS 03, MHH 01, MIC 01]
Source Mean annual effective doseper person [mSv]
Chernobyl NPP accident in the highly contaminated rayons
[for the years 1986-1995 altogether 22.9 mSv]
In the slightly contaminated rayons
[for the years 1986-1995 altogether 7.4 mSv]
Natural background radiation in Germany
(as is typical for Europe in general)
Chernobyl (mean dose in Germany today)
[in 1986: mean dose 0.5 mSv, near the Alps 0.65 mSv, south of
the Danube river 0.35 mSv, north of the Danube river 0.17 mSv]
Nuclear Power Plants in Germany
X-ray computed tomography
X-ray of the chest
Mammography
[if screened every two years between the ages of 50 and 69
altogether 5 mSv]
Flight Paris-Tokyo at 12 000 m
Annual limit for exposed professionals
2.29
0.74
2.4
0.01
<0.01
3-20
0.2
0.5
0.2
20
It must be stressed that ionizing radiation may, even at very low doses at which to date no
such effect has been observed, induce a certain stochastic risk of cancer. As in any risk
assessment, the benefits of an exposure, for example a necessary diagnostic x-ray, must be
weighed against its detrimental effects. And it goes without saying that any unnecessary
exposure should be avoided.
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The hypothetical risk at low doses should therefore be assessed in relation to the order of
magnitude of the radiation doses received from other sources like the natural background
radiation, especially when the exposure in question is the source of massive public concern as
is the case after the Chernobyl accident. Ionizing radiation is a very good example of
discrepancy between the actual risk and the emotions raised: whether a certain risk is
acceptable in the public opinion often depends not so much on the dimension of the risk as on
its perception in a society. Beyond the factual aspect, risk seems to be a socially constructed
concept. Gender, education and social status are strongly correlated with risk judgement and
attitude. There even is a theory that ‘individuals select what and how much to fear as the
product of a particular cultural bias and in order to support a given world view’ [TUB 99].
Whether risks are avoidable clearly has little influence on the risk perception. This becomes
evident when comparing the above-mentioned hypothetical cancer risks at low doses of
radiation with other, real cancer risks. The International Agency for Research on Cancer
estimates that 50% of all cancers could be avoided by changes in lifestyle (less exposure to
tobacco, alcohol, the sun, changes in nutrition, and more physical exercise) [cited in TUB 99].
A special problem in the Commonwealth of Independent States is the actual decline in health
and the increase in mortality in the population, which mainly affects middle-aged men. After
a marked increase in the mid 1980s due to Gorbachev’s anti-alcohol campaign, the male life-
expectancy at birth has dropped by nearly 10 years to presently 56.1 years (Disability
Adjusted Life Expectancy - DALE), while it is still 66.4 years for women [DEM 03].
Incidentally, the infant mortality remained stable during the same period, which indicates that
the health care system in the field of obstetrics and neonatology is – so far – intact. The
decrease in life expectancy is mainly due to deaths from ‘accidents and intoxication’ and from
‘cardiovascular diseases’, whereas the cancer mortality has decreased for both sexes [SKH
99]. Obviously, the unfavourable economic and insecure social situation as well as self-
induced health risks play a major role in the decrease of life-expectancy, but are rarely
consciously associated with it. Yet people tend to attribute any physical symptom to the
radiation factor – regardless of whether they live in a highly contaminated rayon or not.
4.7. RELEVANCE AND IMPLICATIONS FOR PUBLIC HEALTH
The present study was designed to detect a possible increase of leukaemia incidence on the
level of the general population in the rayons of Russia highly contaminated as a result of the
Chernobyl Nuclear Power Plant accident. Although the findings of the study are not
surprising considering the scientific knowledge, they are nevertheless acutely important in
view of the beliefs of the general public.
The fear and apprehension caused by the overestimation of the radiation risks create a
continuous stress situation and add to the present detrimental health conditions in the
population. Moreover, people who attribute the cause of ill health to an external locus of
control are less liable to show positive health behaviour than people with an internal locus of
control. This would, obviously, also affect the degree of counter-measures personally taken
by individuals in the contaminated regions, such as following the special guidelines for the
preparation of food (vegetables, meat, etc.) to reduce the content of radio-nuclides.
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It is therefore of utmost importance to communicate not only the results but also the reliability
of the study and the soundness of the data to the affected people. But even if the general
public might not overcome their mistrust especially of official information, the findings
should at least influence official institutions: ideally, the study should persuade public health
authorities to address the current health problems instead of attributing them to the radiation
factor and remaining inactive.
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5. ABSTRACT
BACKGROUND Leukaemia, especially the acute types predominant in children, may be
caused by ionizing radiation. After the Chernobyl Nuclear Power Plant
accident on 26 April 1986, parts of Belarus, Russia and the Ukraine were
contaminated with radionuclides. To date, over 270 000 people live in
such contaminated regions in Russia. This study investigates whether the
leukaemia incidence rates in these regions might have increased due to
the radiation.
MATERIALS & METHODS A prospective population-based cohort study with a control group was
carried out. Cases of leukaemia previously not registered were actively
sought for in medical and administrative institutions. Each case that had
occurred in the study regions between 1980 and 1998 has been
ascertained and verified. A descriptive analysis was then performed on
the resulting data base which included 333 leukaemia cases.
RESULTS There is a slight secular trend in the standardized incidence rates both in
the highly contaminated and in the control regions. This increase,
however, is more marked in the control regions. The incidence rates in
children (0-14) in the highly contaminated regions decrease between the
pre-accident (1980 to 1986) and the first post-accident period (1987-
1992) and show a slight increase towards the second post-accident
period (1993-1998), whereas the incidence rates in the control regions
show exactly the opposite dynamic. This makes a connection between
the dynamics of the incidence rates and the radiological situation highly
improbable.
The comparative analysis of the leukaemia incidence rates has not
revealed a statistically significant difference between the population of
the highly contaminated regions of the Bryansk oblast and the combined
control regions of the Kaluga oblast.
CONCLUSIONS There is so far no indication of an increase in leukaemia incidence rates
in the general population, neither for children nor for adults. This does
not contradict the current radiobiological knowledge that cancer,
especially leukaemia, can be caused by ionizing radiation. The number of
expected radiation-induced cases based on the risk estimates from the
Japanese cohort lies within the 95% confidence limits of the spontaneous
incidence rates. It would therefore, if at all present, not be statistically
detectable in a population of 222 000 with a spontaneous rate of
5.4/100 000 in men and 3.3/100 000 in women in the control regions.
Considering the latency periods and the age-dependent risk-curve of
radiation-induced cancers, it is highly unlikely that a radiation-related
increase in leukaemia or solid tumour incidence rates will become
obvious in the future.
The fear and apprehension caused by the overestimation of the radiation
risks create a continuous stress situation and add to the present
detrimental health conditions in the population. It is therefore of utmost
importance to communicate not only the results but also the reliability of
the study and the soundness of the data to the affected people.
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5. ZUSAMMENFASSUNG
HINTERGRUND Leukämien, insbesondere die akuten Formen, die im Kindesalter
vorherrschen, können durch radioaktive Strahlung induziert werden.
Durch den Unfall in Tschernobyl am 26. April 1986 sind Teile von Belarus,
Russland und der Ukraine radioaktiv kontaminiert worden. Bis heute
leben in Russland über 270.000 Menschen in solchen kontaminierten
Gebieten. Die vorliegende Studie untersucht, ob die Leukämieinzidenzen
in diesen Gebieten aufgrund der radioaktiven Strahlung angestiegen sind.
MATERIAL & METHODEN Zu diesem Zweck wurde eine bevölkerungsbezogene, prospektive
Kohortenstudie mit einer Kontrollgruppe durchgeführt. Jeder Leukämiefall
der Jahre 1980-1998 aus den Studienregionen wurde genau nacherhoben
und verifiziert. Zudem wurde aktiv in Krankenhäusern und Behörden
nach nicht erhobenen Fällen gesucht. Die 333 Leukämiefälle, die sich
letztendlich in der Datenbank befanden, wurden deskriptiv analysiert.
ERGEBNISSE Die standardisierten Inzidenzen zeigen über die Jahre einen leicht
ansteigenden Trend, sowohl in den kontaminierten als auch in den
Kontrollregionen. Dieser Anstieg ist ausgeprägter in den Kontrollregionen.
Die Inzidenzen bei Kindern (0-14 Jahre) fallen in den kontaminierten
Regionen zwischen der Periode 1980-86 und der Periode 1987-1992 ab
und steigen dann in der Periode 1993-98 wieder leicht an, wohingegen
die Inzidenzen in den Kontrollregionen genau die umgekehrte Dynamik
zeigen. Dies macht einen Zusammenhang mit der radioaktiven Strahlung
höchst unwahrscheinlich.
Die vergleichende Analyse zeigt keinen statistisch signifikanten
Unterschied in den Inzidenzen zwischen den kontaminierten Regionen
und den Kontrollregionen.
SCHLUSSFOLGERUNGEN Es gibt keinen Hinweis auf einen Anstieg der Leukämieraten in der
Allgemeinbevölkerung, weder bei Kindern noch bei Erwachsenen. Dies
widerspricht nicht der strahlenbiologischen Erkenntnis, dass Tumoren,
insbesondere Leukämien, durch radioaktive Strahlung induziert werden
können. Die mittels der Risikokoeffizienten aus den japanischen Studien
errechnete Anzahl der strahleninduzierten Leukämiefälle liegt innerhalb
der 95% Konfidenzintervalle der jährlichen Fluktuation der Spontanraten.
Solch induzierte Fälle wären daher – falls vorhanden – bei einer
exponierten Bevölkerung von ca. 222.000 und einer in den Kontroll-
regionen beobachteten Spontanrate von 5,4/100.000 (Männer) bzw.
3,3/100.000 (Frauen) statistisch nicht nachweisbar. Bedenkt man die
Latenzzeiten und die altersabhängige Risikostruktur strahleninduzierter
Tumore, ist ein Anstieg sowohl der Leukämieraten als auch der Raten
solider Tumore aufgrund des Reaktorunfalls in Tschernobyl in der
Zukunft extrem unwahrscheinlich.
Die Ängste und Befürchtungen, die durch die Überschätzung der Risiken
durch die radioaktive Strahlung entstanden sind, haben zu einer
persistierenden Stresssituation für die Betroffenen geführt. Dieser Stress
wirkt sich zusätzlich zu den aktuellen ökonomischen und sozialen
Faktoren negativ auf die Gesundheit der Bevölkerung aus. Es ist daher
wichtig, den Betroffenen nicht nur die Ergebnisse der vorliegenden
Studie, sondern insbesondere auch die Qualität der zugrunde liegenden
Daten glaubwürdig zu vermitteln.
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6. ABBREVIATIONS
ALL (204.0) acute lymphoid leukaemia
ALNOS (208.0) acute leukaemia, not otherwise specified
AML (205.0) acute myeloid leukaemia
AUL (208.0) acute undifferentiated leukaemia
BOC Bryansk Oblast Clinic
БОБ – Брянская областная больница
BOOD Bryansk Oblast Oncological Dispensary
БООД – Брянский областной онкологический диспансер
BOPC Bryansk Oblast Paediatric Clinic
БОДБ – Брянская областная детская больница
Bq Becquerel
BY Belarus
CC City Clinic
ГБ – городская больница
CD Cluster of Differentiation
CDL Clinical-Diagnostic Laboratory
КДЛ – клинико-диагностическая лаборатория
95%-CI 95%- confidence interval
Ci Curie
CIS Commonwealth of Independent States (founded in December 1992.
Members are: Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan,
Kyrgystan, Moldova, Russia, Tajikistan, Turkmenistan, Uzbekistan and
the Ukraine)
CLL (204.1) chronic lymphoid leukaemia
CML (205.1) chronic myeloid leukaemia
CMMoL chronic myelomonocytic leukaemia
CLNOS (208.1) chronic leukaemia, not otherwise specified
CR Cancer Registry
CRC Central Rayon Clinic
ЦРБ – центральная районная больница
DCO Death Certificate Only
df degree(s) of freedom
EST Esterase
ERR Excess Relative Risk
Gosagroprom State Committee of Agricultural Industry
Goskomepidnadzor State Committe of Epidemiological Surveillance
Goskomgidromet State Committee of Hydrometeorology of the USSR
Gy Gray
IARC International Agency for Research on Cancer
ICD-9 International Classification of Diseases, Injuries and Causes of Death, 9th
Revision
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KOC Kaluga Oblast Clinic
КОБ – Калужская областная больница
КOOD Kaluga Oblast Oncological Dispensary
КООД – Калужский областной онкологический диспансер
KOPC Kaluga Oblast Paediatric Clinic
КОДБ – Калужская областная детская больница
LDH Laktate Dehydrogenase
LNOS (208.9) leukaemia, not otherwise specified
LET Linear Energy Transfer (of different types of radiation)
MDS Myelodysplastic syndromes
МДС – Миелодиспластический синдром
MRRC RAMS Medical Radiological Research Centre of the Russian Academy of
Medical Sciences
МРНЦ РАМН – медицинский радиологический научный центр
Российской академии меднаук
OAL (206.0, 207.0) other acute leukaemia
OC Oblast Clinic
ОБ - областная больница
OCL (205.8, 207.1) other chronic leukaemia
OOD Oblast Oncological Dispensary
ООД- областной онкологический диспансер
OPC Oblast Paediatric Clinic
ОДБ – областная детская больница
PAL Patho-Anatomical Laboratory
ПАЛ -патолого-анатомическая лаборатория
PAS Periodic Acid-Schiff Reaction
POC Paediatric Oblast Clinic
ДОБ детская областная больница
POX Peroxidase
RAEB (284.9) refractary anaemia with excess blasts
РАИБ - рефрактерная анемия с избытком бластов
Rosgydromet Federal Service for Hydro-meteorology and Environmental Monitoring
RR Relative Risk
RU Russia
Sv Sievert
UA Ukraine
ZAGS Vital Registration Department
ЗАГС – Запись актов гражданского состояния
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7. GLOSSARY
Absorbed dose: Energy which is transferred by radiation to matter per unit mass. This dose is given in
Gray (Gy), where 1 Gy = 1J/kg.
Becquerel: measure for the activity of radionuclides, i.e. for the number of decays per time interval,
where 1 Bq = 1 decay/sec.
Blast cells: undifferentiated blood cells which are normally found in the bone marrow and only in
very small quantities in the peripheral blood.
Cancer Registry: the term Cancer Registry is used – if not otherwise stated – for population based
cancer registries.
95%-Confidence interval (95%-CI): Range around a mean in which 95% of the values of a sample
survey are located. For a Poisson distribution this is approximately:
95%-CI = [n – 1.96*√n; n + 1.96*√n].
Dispensary  (диспансер): specialized (in view of the disease) therapeutic and prophylactic institution
which screens for, treats and registers patients with a specific disease. Additionally, definite
population groups are monitored to prevent a disease or the spreading of a disease. [MDF 92]
Dispenserisation  (диспансеризация): screening and therapeutic monitoring of an entire population.
The responsibility of the dispensary follows the place of residence, i.e. the population is monitored
entirely without overlap. The monitored population is regularly invited for screening. Patients are
treated with the most modern methods (available author’s comment). Prophylactic measures and
amelioration of the environment is part of the dispensarisation. [MDF 92]
Equivalent dose: different types of radiation vary in their relative biological effectiveness (RBE). To
obtain the equivalent dose, the absorbed dose (↑) is multiplied with an official radiation-specific
weighting factor (wR) that is set by the International Commission on Radiological Protection (ICRP);
for example, wR for photons (γ- or x-rays) is 1, for neutrons it is 20. The equivalent dose is given in
Sievert (Sv), where 1Sv = 1 J/kg.
Excess Relative Risk (ERR): relative risk (↑) exceeding 1. ERR=RR-1= CIEX/CINon-EX-1.
Expectation bias: increased perception (and registration) of (presumed) effects because of the
expectation of the observer.
Gray: unit of the absorbed dose (↑), where 1 Gy = 1J/kg
Incidence: (rate) describes the occurrence of a disease in relation to a population over a specified time
interval. It is usually given per 100 000 persons.
I = cases in the time interval x / mean population in the time interval x.
Khozraschet  (хозрасчет): economic tendering of account. Important constituant of the perestroika
(↑) under Gorbachev, in which state-owned enterprises were expected to produce economically.
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Low dose: often not specified. The United Nations Scientific Committee on the Effects of Atomic
Radiation (UNSCEAR) defines low dose as dose below 200 mSv [UNS 00].
Median: middle-valued observation when all the observations are ranked in order of value [MOU 98].
Oblast (областъ): administrative subunit of a republic of the former Soviet Union. They are formed
on the grounds of the number of inhabitants, not on geographic or historic features. The population of
an oblast is 1.5 – 2 million and, correspondingly, they vary a lot in geographic size. Oblasts are further
subdivided into rayons (↑).
Oncological dispensary: (↑Dispensary) institution specialized in screening, therapy, follow-up and
registration of a specific disease.
Perestroika (перестройка): rebuilding. Term introduced politically by Gorbachev for the
restructuring of governmental and societal structures of the Soviet Union.
Poisson-distribution: describes the probability of events in space or time which occur at a defined
frequency.
Power: 1 - β, i.e. 1 – the probability of erroneously accepting the null-hypothesis.
Proliferation, clonal: growth by division of a single cell. Formation of a clone, i.e. a group of
genetically identical cells.
Radioactivity: decay of atomic nuclei, the so-called radionuclides. Radionuclides transform into other
nuclides e.g. by emitting specific radiation such as α-, β-, or γ-radiation. There are natural as well as
man-made radionuclides. The activity of nuclides is measured as the number of decays per time
interval. Its unit is Becquerel, where 1 Bq = 1 decay/sec.
Rate: (↑) Incidence.
Rate Ratio: ratio of two rates (incidences) (↑)
Rayon  (район): administrative subdivision of an oblast (↑) or a larger town. A rayon has 70 000 –
150 000 inhabitants.
Relative Risk (RR): measure to describe the effect of a harming agent. The RR is the ratio of the
probability to incur a disease for the exposed (CIEX) versus the non-exposed (CINon-EX).
RR= CIEX/CINon-EX.
Screening: examination of groups of population (population at risk) in order to detect certain diseases
at an early stage.
Sievert: unit for the equivalent dose (↑), where 1Sv = 1 J/kg.
Uchastok  (участок): smallest unit for the delivery of public health care, administrative subdivision
of a rayon (↑). The uchastok comprises 3 000 – 4 000 persons, to whom primary health care is
delivered by a general practitioner, a gynaecologist and obstetrician, a paediatrician, and several
nurses.
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NOTE
When transferring the cyrillic alphabet into latin, an English phonetic transcript was used
rather than a scientific transcript. Probably because of its distribution in the World Wide Web,
the phonetic transcript has been widely accepted in the past years in preference to other
systems.
Words and geographic names as well as names that are customarily spelt deviantly from the
phonetic system are spelt in the customary way.
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SOME IMPORTANT FRAGMENTS FROM THE METHODOLOGICAL RECOMMENDATIONS:
“1.5. The mean cumulative effective dose received by all residents of the settlement has been
conservatively admitted to be the mean cumulative dose in adults. According to the
dosimetric surveillance of the population in the regions contaminated after the Chernobyl
accident in the period from 1986 to 1995, the mean annual effective dose to children of
various ages did not exceed the mean dose to adults of the same settlement.
1.7. The external radiation dose is the dose due to γ-radiation of all deposited radionuclides
with a half-life ranging from several hours to 30 years. The contribution of each of the
radionuclides to the dose accumulated for 9.7 years (from 1986 to 1995) exceeds 0.1%.
According to modelled estimations, the effective dose due to β- and γ-radiation directly from
the radioactive cloud that moved over the settlements of the Russian Federation was less than
5% of the mean cumulative dose for the first year following the accident and is not taken into
consideration in the current methodological recommendations. Modelled estimations showed
that the contribution of external distant and contact exposure of the skin to β-emitted
radionuclides is negligible and has therefore not been accounted for in the recommendations.
1.8. The internal radiation dose is due to 137Cs, 134Cs, 90Sr, 89Sr which enter the body via
foodstuffs. A contribution of the inhaled radionuclides to the internal radiation dose from both
the radioactive cloud and resuspension of the deposited radionuclides has not been accounted
for except for 137Cs and 134Cs. …The results of autopsy tissue of residents of the Bryansk
oblast showed that the contribution of isotopes of plutonium to the effective dose did not
exceed 1%. The contribution of other radionuclides - except for those mentioned above - that
were deposited on the surface of vegetables shortly after the Chernobyl accident and
accumulated for 9.7 years was also negligible.“ [MER 96]
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DETAILED DESCRIPTION OF THE VERIFICATION PROCESS
The correct diagnosis and up-to-date classification of leukaemia and lymphomas remains one
of the most difficult diagnostic procedures in contemporary medicine.
The basis for the classification of the various cytological forms of leukaemia is the
microscopic examination of blood and bone marrow smears, spinal fluid and exudation in
serous spaces. Depending on the type of leukaemia and the individual course of the disease,
further histological study of biopsies of lymphatic nodes or bone marrow may be necessary
[GLU 98]. A more detailed classification of the type of the transformed cells is achieved by
cytochemical methods [GLU 78, HAY 88]. Most of the haemato-oncological departments and
laboratories of the city and oblast clinics, including the oncological dispensaries, are now able
to carry out such procedures at reasonable quality [FAJ 80]. A contemporary diagnosis though
requires supplementary immunophenotyping of the leukaemic cells as well as cytogenetic and
molecular genetic analysis – technologies which were introduced only lately in the countries
of the CIS [BAR 97, GLU 00a, BAI 01, LUG 01]
These new technologies have revolutionized the classification of leukaemia [BEN 95, BAI 99,
WIL 99] and led to changes, leaving some classes of the ICD 9 incompatible with the ICD 10.
A review of the cases diagnosed earlier thus led to new classification of some of the cases as
formerly unknown subtypes of leukaemia.
However, as this study is conducted retrospectively on cases which have been diagnosed and
classified mainly based on the morphological and cytochemical analysis of blood and bone
marrow cells, the ICD 9 classification is preserved.
One of the difficulties in the verification of correct diagnoses is acute leukaemia of
unspecified cell type (ICD 9: 208.0): This code may actually be attributed in two different
cases, namely to 1) acute leukaemia, not otherwise specified (ALNOS) and 2) acute
leukaemia of unspecified cell type. In the haematological departments of Russia (and formerly
of the Soviet Union), such cases were identified as acute undifferentiated leukaemia (AUL)
[FAJ 80, GLU 00]. As a rule, non-verified acute leukaemia, not otherwise specified (ALNOS)
were found only in cancer registration documents. In some cases, the initial medical
document could not be traced, in all other cases the diagnosis had been established
posthumously, when cytochemical or other typing of the blast cells was impossible. If, on the
other hand, the diagnosis 208.0 had been verified, the case was cytochemically and –
sometimes - immunologically typed as acute undifferentiated leukaemia [BEN 95]. Some
authors believe such leukaemia to be lymphoid [LUD 94] or myeloid [BEN 91, BEN 97, FRE
98], others postulate the existence of a biphenotypic form [HAN 93, LEN 99]. Even if these
undifferentiated forms are extremely rare (1-2,5% of all cases of acute leukaemia), the cases
in the study were taken as verified, as there were convincing indications in the medical
histories.
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From the point of view of classification, another veritable difficulty with using the ICD 9 is
the absence of a code for myelodysplastic syndromes (MDS). All present classifications
contain information about this clonal disease of the bone marrow, which develops on the
grounds of a disorder of the stem cell [BEN 85, AUL 94, ROS 96, BEN 97, GUS 99, GLU
01]. MDS often transform into acute leukaemia [TRI 92], a number of MDS are thus assessed
as preleukaemic conditions. Ukrainian authors have found that acute myeloid leukaemia in
persons who had been irradiated due to the ChNPP accident is often preceded by MDS [SIV
01]. In the Russian haematological departments, some forms of MDS with a small share of
blast cells were described as small-percentage leukaemia, which corresponds to leukaemia
with low count of blasts.
The FAB classification, which accounts for the various forms of MDS, was used in the more
important haematological centres in Russia since the middle of the 1980s. According to the
FAB classification, the diagnosis leukaemia with low count of blasts which usually types as
myeloid or myelomonoblast, corresponds to refractary anaemia with excess blasts (RAEB).
RAEB is found in children as well as in adults [HAS 94, IVA 94, PAS 95].
Decisive for the diagnosis RAEB is the presence of 5-20% of blast cells in the bone marrow
and up to 5% of blast cells in the peripheral blood in contrary to the diagnosis acute myeloid
leukaemia which demands 30% blast cells in the bone marrow. RAEB is no longer a category
of the myelodysplastic syndromes in the ICD 10 and all conditions in which myeloid blast
cells in the bone marrow exceed 20% are classified as acute myeloid leukaemia.
According to WHO recommendations, even myelodysplasia with low count of blasts in the
bone marrow – which were formerly diagnosed as myelodysplastic syndromes (in Russia:
refractary anaemia with excess blasts OR acute leukaemia with low count of blasts) – should
now be diagnosed as acute myeloid leukaemia [GLU 01]. In this study, two such cases were
found in the medical histories, where the diagnosis acute leukaemia with low count of blasts
was attributed along with the diagnosis MDS, RAEB. Those cases were coded as 205.0, i.e.
acute myeloid leukaemia.
The myelodysplastic syndromes are known to be inducible by radiation just as acute
leukaemia and chronic myeloid leukaemia [GLU 96, BEB 99], they are thus analysed together
in this study.
The data collection, ascertainment and verification was carried in the oblast and rayon clinics
where the initial medical documents are stored. The results of all the information found
during the verification process was entered into a specially designed Verification Card for
Leukaemia Cases (fig. A2.1).
ANNEXE 2 A4
The process of collection, ascertainment and verification is a multilevel process:
1ST LEVEL
Institution: Oblast Oncological Dispensary (OOD)
Source: Control Card of the cancer patient
The analysis of the Control Cards allows the comparison with the information that is stored in
the database of the cancer registry. If inconsistencies are found, further research in other
medical documents and institutions is initiated. The information on the Control Card consists
of:
1.1. Surname, name, patronymic
1.2. Year of birth
1.3. Place of residence
1.4. Full written diagnosis, including clinical (acute, chronic) and cytological (myeloid,
lymphoid, other) characteristics
1.5. ICD-9 code
1.6. Date of registration of the patient at the OOD
1.7. Date of exclusion of the patient from the files of the OOD
1.8. Information about in-patient treatment or other medical consultations
1.9. Diagnosis was made on the grounds of:
1.9.1. blood analysis
1.9.2. bone marrow punction
1.9.3. clinical picture
1.9.4. histological findings
1.10. instructions for autopsy
1.11. date of death
Cases were actively sought for in the registries of other blood disorders at the OOD:
- anaemia
(of uncertain aetiology, hypoplastic, refractory, vit-B12-deficiency, autoimmune, etc.)
- lymphoma
- leukaemoid reaction
- thrombocytopaenia of uncertain aetiology
- cytopaenia.
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Name, surname Card number Sex Date of birth Address Rayon code Date of death
Code of
disease Verifi. code
Date of
diagnosis Verifi. date Age
Method of
verification Diagnosis (text)
SOURCES OF THE DATA
1. Medical History yes□ no□
2. Out-patient Card yes□ no□
3. Control Card of dispensary follow-up yes□ no□
4. Notification of a cancer case diagnosed for the first time yes□ no□
5. Records in the journal of Clinical-Diagnostic Laboratory yes□ no□
6. Blood smears yes□ no□
7. Blood analyses (text) yes□ no□
8. Bone marrow smears yes□ no□
9. Other medical documents yes□ no□
10. Journals of the oncological consulting cabinet at the CRC yes□ no□
CRITERIA FOR THE DIAGNOSIS
1. Blood analyses (text) _____________________________________________
2. Myelograms ____________________________________________________
2.1 Cytochemical analyses ___________________________________________
3. Bone marrow biopsies ____________________________________________
4. Patho-anatomical analyses _________________________________________
5. Immunological analyses ___________________________________________
6. Lymphatic node biopsies __________________________________________
7. Cytogenetic analyses _____________________________________________
8. Blood cell culture analyses_________________________________________
9. Hepatomegaly yes□ no□
10. Splenomegaly yes□ no□
11. Haemorrhagic syndrome yes□ no□
12. Lymphadenopathy yes□ no□
13. Articular syndrome yes□ no□
14. Other criteria ___________________________________________________
Medical comment__________________________________________________
Fig A2.1. Verification Card for Leukaemia Cases
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In some of the OODs, as in the Kaluga OOD, there is a medical out-patient card for each
patient which contains further information such as the Notification of a cancer case diagnosed
for the first time, epicrises of varying length on hospitalisation, results of blood analyses or
bone marrow punctions, consultations of haematologists etc.
2ND LEVEL
Institution: Oblast Clinic (OC) or Oblast Paediatric Clinic (OPC)
Source: Medical History of the in-patient
Practically all leukaemia patients who were diagnosed at a rayon clinic come to the oblast
out-patient department for further haematological consultation. In most cases, those patients
then undergo treatment at the oblast clinic or the oblast paediatric clinic. An exception to this
rule are patients with uncomplicated forms of CLL or CML with unequivocally established
diagnoses and no need for hospitalisation.
The oblast clinics have, as a rule, specialized haematological departments as well as a
consultant haematologist in the out-patient department. The in-patients’ Medical Histories are
kept in the archives of the OC, the Out-patient Cards in the registration offices of the out-
patient departments. With help of the Medical histories, the following information is verified:
2.1. Surname, name, patronymic
2.2. Year of birth
2.3. Place of residence
2.4. Duration of hospitalisation
2.5. Full clinical diagnosis
2.6. Date of diagnosis
2.7. Anamnestic data and the results of diagnostic procedures that had been carried out in
other medical institutions (Russian Haematological Research Centre, Russian
Oncological Research Centre). Verified date of diagnosis
2.8. Clinical signs of leukaemia (hepato-splenomegaly, haemorrhagic syndrome, lymph node
status, etc.)
2.9. Results of all blood analyses
2.10. Results of all bone marrow punctions
2.11. Other diagnostic procedures (bone marrow biopsies, lymph node biopsies, biochemical,
immunological and cytogenetic analyses)
2.12. Autopsy-protocols
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3RD LEVEL
Institution: Laboratories of the OC and the OPC
Source: Journal of Diagnostic Procedures
These journals are kept at the archives of the clinical laboratories at the oblast clinics. Results
of the following procedures and analyses are recorded:
3.1. Myelograms
3.2. Cytochemical typing
3.3. Immunological typing
3.4. Cytogenetic typing
This information allowed to make the diagnosis more specific in several cases, thus
ameliorating the level of verification.
4TH LEVEL
Institution: Laboratories of the OC and the OPC
Source: Archives of blood and bone marrow smears
4.1. Bone marrow smears, stained with standard methods
4.2. Blood and bone marrow smears which underwent cytochemical methods
4.2.1. Myeloperoxidase
4.2.2. Lipids
4.2.3. PAS reaction against glycogen
4.2.4. Unspecific esterase
4.2.5. Acid phosphatase
The work with the morphological and cytochemical smears revealed some cases in which the
morphological picture did not show a leukaemia, but e.g. a multiple myeloma, aplastic
anaemia etc. Those cases had been added to the database at the stage of verification of the
diagnosis, when the diagnosis was changed due to further analyses (repeated bone marrow
punction, consultation of medical institutions in Moscow etc.). The same research was carried
out for histological material (bone marrow biopsies, lymph node biopsies) and for the biopsies
taken during autopsies at the patho-anatomical laboratories of the oblast clinics.
5TH LEVEL
Institution: All out-patient departments of the OC and the OPC
Source: Out-patient Card
The Out-patient Card contains information on further diagnosis as well as the treatment
performed by the haematologist at the OC or the OPC
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6TH LEVEL
Institution: Central Rayon Clinic (CRC)
Source: Out-patient Card
The most valuable source of information is the central rayon clinic, where the initial Out-
patient Cards on all patients are kept. The Out-patient Card, as a rule, contains information
from the first visit because of a haematological disease, such as all blood analyses, extracts
from the medical histories after hospitalisation etc. The archives of the CRC also allowed the
verification of the date and cause of death of deceased patients.
The ascertainment and verification on these six levels led to changes in the database, namely
to the exclusion of cases in which the diagnosis leukaemia proved to be incorrect for various
reasons.
72% (18) of all necessary changes (25) concerned chronic leukaemia, the vast majority of
which were CLL. 50% (8 cases) of the cases recorded as CLL turned out to be Non-
Hodgkin’s lymphomas (200.1) after biopsy of lymphatic nodes. Indeed, CLL may be hard to
distinguish from a differentiated lymphoma [COM 80, MIN 83]. 44% (7 cases) of CLL
(204.1) were in reality multiple myelomas (203.0), but had been miscoded by the medical
statistician when transferring the information from the Notification to the Control Card. The
analysis of the medical histories, laboratory results, and myelograms supported the fact that
there had been a technical mistake. This was confirmed by the verification of bone marrow
smears within the framework of this study. Another case (6%) of CLL was also due to
miscoding in the Control Card and the diagnosis was subsequently changed to
lymphogranulomatosis (201). In one case, a miscoding error in the Control Card had led to
the classification of a lymphatic metastasis (196.9) as leukaemia (208.9).
In 6 cases (24%) of the 25 cases in which the diagnosis could not be confirmed, various
pathologies (anaemia (285), megaloblastic anaemia (281.0), death before diagnosis without
autopsy (798.2)) were provisionally coded as acute leukaemia (208.0) in the Control Card.
The diagnosis later remained unchanged in the Control Card, even though the revised
diagnosis was unequivocal on the basis of the diagnostic procedures and had been changed in
the medical histories. A list of all diagnoses changed is given in table 2.11 in the main text.
Table A2.1 gives the number of cases that were verified for the Bryansk and for the Kaluga
oblasts with help of the various sources. It shows only those cases used for the
epidemiological analysis (333), the 34 cases that were excluded on the basis of the
verification were not taken into account.
In all cases that had occurred in the Bryansk oblast, a corresponding Control Card and in
more than 40% of the cases, a Medical History was found. In some cases, even 3-5 Medical
Histories could be allocated to one case if the patient had been treated repeatedly or in
different in-patient institutions. Information from the diagnostic and pathological laboratories
of the Bryansk oblast clinic and paediatric clinic was accessible in more than 30% of the
cases.
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Table A2.1 Sources for the verification of data in the Bryansk and the Kaluga oblasts
Number of cases 1980 – 1998
Highly contaminated Slightly contаminated Control
n=247 n=45 n=41SOURCES FOR QUALITY CONTROL
No % No % No %
Notification or Control Card of the
OOD 247 100 27 60.0 25 61.0
Out-patient Card (OODs, OCs,
CRCs) 10 4.0 41 91.1 40 97.6
Medical History (OCs, OPCs,
CRCs) 107 43.3 18 40.0 20 48.8
Histological archives of the CDL &
PAL of the OCs* 73 29.5 21 46.7 12 29.3
Bone marrow smears 24 9.7 8 17.8 2 4.9
Blood analyses (text) 99 40.1 20 44.4 27 6.6
Bone marrow smears (text) 87 35.2 9 20.0 9 21.9
Cytochemical analyses 44 17.8 3 6.7 2 4.9
Immunol. / cytogen. tests 38 15.4 2 4.4 2 4.9
Clinical symptoms 74 29.9 10 22.2 8 19.5
Diagnosis was established at / in:
Moscow 4 1.6 2 4.4 2 4.9
Oblast Clinic 122 49.4 37 82.3 32 78.0
City Clinic, Central Rayon Clinic 121 49.0 6 13.3 7 17.1
*Histological archives of the CDL & PAL of the ВOC: journals of myelograms, patho-
anatomical comments, results of lymphatic node biopsies
The verification of diagnoses in Kaluga was performed mainly on the grounds of the Out-
patient Cards of the oncological dispensaries, the oblast clinic out-patients department and the
central rayon clinics. In over 40 % of all cases, Medical Histories of hospitalised patients
were consulted. Usually, patients would be diagnosed and treated in the specialized
haematological departments of the Kaluga oblast clinic or paediatric clinic. In some cases,
when the Medical History could not be found in the archives or was illegible (because of the
physical conditions in the archives), the information was traced in the diagnostic and
pathological laboratories of the Kaluga oblast clinic. Apart from that, all cases had been
registered at the oncological cabinet of the central rayon clinic, were the journals of newly
diagnosed leukaemia cases and of deaths of cancer patients were analysed.
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Table A2.2 Leukaemia cases by subtypes and periods in the rayons under study (adults)
1980-1986 1987-1992 1993-1998
Highly
contam.
Slightly
contam. Control
Highly
contam.
Slightly
contam. Control
Highly
contam.
Slightly
contam. Control
Total
TYPE OF
LEUKAEMIA No % No % No % No % No % No % No % No % No % No %
ALL204.0 2 3.08 2 15.38 - - 10 13.89 - - - - 9 10.84 1 4.35 1 6.25 25 8.39
AML 205.0 /
OAL 206.0, 207.0
1 1.54 4 30.77 2 18.18 15 20.83 - - 1 11.11 12 14.46 4 17.39 1 6.25 40 13.42
ALNOS 208.0 13 20 2 15.38 2 18.18 8 11.11 1 16.67 - - 3 3.61 - - - - 29 9.73
ANL 208.0 - - - - - - - - 1 16.67 - - 3 3.61 1 4.35 1 6.25 6 2.01
CLL 204.1 13 20 1 7.69 6 54.55 23 31.94 2 33.33 4 44.44 31 37.35 11 47.83 7 43.75 98 32.89
CML 205.1 /
OCL 205.8,207.1
6 9.23 4 30.77 1 9.09 8 11.11 2 33.33 3 33.33 25 30.12 6 26.09 5 31.25 60 20.13
CLNOS 208.1 12 18.46 - - - - 6 8.33 - - - - - - - - - 18 6.04
LNOS 208.9 18 27.69 - - - - 2 2.78 - - 1 11.11 - - - - 1 6.25 22 7.38
Total  204.0-208.9 65 100 13 100 11 100 72 100 6 100 9 100 83 100 23 100 16 100 298 100
Table A2.3 Leukaemia cases by subtypes and periods in the rayons under study (children)
1980-1986 1987-1992 1993-1998
Highly
contam.
Slightly
contam. Control
Highly
contam.
Slightly
contam. Control
Highly
contam.
Slightly
contam. Control
Total
TYPE OF
LEUKAEMIA No % No % No % No % No % No % No % No % No % No %
ALL 204.0 11 78.57 - - - - 4 80 - - 3 75 8 100 1 50 1 100 28 80
AML 205.0 /
OAL 206.0, 207.0
2 14.29 1 100 - - - - - - - - - - 1 50 - - 4 11.43
ALNOS 208.0 1 7.14 - - - - - - - - - - - - - - - - 1 2.86
CML 205.1 /
OCL 205.8,207.1
- - - - - - 1 20 - - - - - - - - - - 1 2.86
LNOS 208.9 - - - - - - - - - - 1 25 - - - - - - 1 2.86
Total  204.0-208.9 14 100 1 100 0 0 5 100 0 0 4 100 8 100 2 100 1 100 35 100
Table A2.4 Leukaemia cases by subtypes and periods in the rayons under study (all cases)
1980-1986 1987-1992 1993-1998
Highly
contam.
Slightly
contam. Control
Highly
contam.
Slightly
contam. Control
Highly
contam.
Slightly
contam. Control
Total
TYPE OF
LEUKAEMIA No % No % No % No % No % No % No % No % No % No %
ALL 204.0 13 16.46 2 14.29 - - 14 18.18 - - 3 23.08 17 18.68 2 8 2 11.76 53 15.92
AML 205.0 /
OAL 206.0, 207.0
3 3.80 5 35.71 2 18.18 15 19.48 - - 1 7.69 12 13.19 5 20 1 5.88 44 13.21
ALNOS 208.0 14 17.72 2 14.29 2 18.18 8 10.39 1 16.67 - - 3 3.30 - - - - 30 9.01
ANL 208.0 - - - - - - - - 1 16.67 - - 3 3.30 1 4 1 5.88 6 1.80
CLL 204.1 13 16.46 1 7.14 6 54.55 23 29.87 2 33.33 4 30.77 31 34.07 11 44 7 41.18 98 29.43
CML 205.1 /
OCL 205.8, 207.1
6 7.59 4 28.57 1 9.09 9 11.69 2 33.33 3 23.08 25 27.47 6 24 5 29.41 61 18.32
CLNOS 208.1 12 15.19 - - - - 6 7.79 - - - - - - - - - - 18 5.41
LNOS 208.9 18 22.78 - - - - 2 2.60 - - 2 15.38 - - - - 1 5.88 23 6.91
Total  204.0-208.9 79 100 14 100 11 100 77 100 6 100 13 100 91 100 25 100 17 100 333 100
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Table A2.5 Leukaemia cases by subtypes for the entire period (1980-1998) in the rayons
under study (all cases)
Number of cases 1980-1998
Highly
contaminated
Slightly
contaminated Control
Total
TYPE OF LEUKAEMIA
No % No % No % No %
ALL 204.0 44 17.81 4 8.89 5 12.20 53 15.9
AML 205.0 / OAL 206.0, 207.0 30 12.15 10 22.22 4 9.76 44 13.2
ALNOS 208.0 25 10.12 3 6.67 2 4.88 30 9.0
ANL 208.0 3 1.21 2 4.44 1 2.44 6 1.8
CLL 204.1 67 27.13 14 31.11 17 41.46 98 29.4
CML 205.1 / OCL 205.8,207.1 40 16.19 12 26.67 9 21.95 61 18.4
CLNOS 208.1 18 7.29 - - - - 18 5.4
LNOS 208.9 20 8.10 - - 3 7.32 23 6.9
Total  204.0-208.9 247 100 45 100 41 100 333 100
Verification was difficult for various reasons
- In accordance with the official requirements, the clinical or even cytological type of
leukaemia was often not given when the case was reported to the OOD.
- Diagnostic materials (blood and bone marrow smears), according to the regulations of
the Russian Federation (and formerly the Soviet Union), only have to be stored for five
years. The smears are not treated for conservation, as is the case for histological slides,
so that the stain discolours and they become worthless for verification.
- Journals in which laboratory results (of bone marrow punctions and biopsies,
lymphatic node biopsies, immunological etc. analyses) are recorded, are often stored
for not more than five years.
- Many of the archives at the oblast, city and rayon clinics are insufficient for extended
storage of papers, so that some of the initial medical documents could not be retrieved.
- The diagnostic process itself suffered from inadequacy to distinguish some types of
leukaemia during the study period.
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CONFIRMATION   -   BESTÄTIGUNG
Ich erkläre hiermit, die vorliegende Dissertation am Medical Radiological Research Centre
(MRRC) of the Russian Academy of Medical Sciences (RAMS), Obninsk, Russland, und am
Strahlenbiologischen Institut der Ludwig-Maximilians Universität, München, Deutschland,
selbständig angefertigt zu haben. Außer der angegebenen Hilfsmittel habe ich mich keiner
weiteren Hilfsmittel bedient. Erkenntnisse, die aus dem Schrifttum ganz oder annähernd
übernommen sind, habe ich als solche kenntlich gemacht und nach ihrer Herkunft unter
Bezeichnung der Fundstelle einzeln nachgewiesen.
Die für die Dissertation verwendeten Daten wurden mir vom Direktor des MRRC RAMS,
Professor VK Ivanov, zu diesem Zweck ausdrücklich zur Verfügung gestellt (siehe folgende
Seite).
Ich habe bisher an keiner in- oder ausländischen Medizinischen Fakultät bzw. keinem
Medizinischen Fachbereich ein Gesuch um Promotion eingereicht – weder über dieses, noch
über ein anderes Thema.
Teile der vorgelegten Arbeit werden im Rahmen folgender Arbeiten veröffentlicht:
- Ivanov VK, Tsyb AF, Gorski AI, Nilova EV, Ivanova LV, Maksioutov MA, Khait SE,
Becker SI, Kellerer AM (2003) Radiation-epidemiological analysis of leukaemia incidence
among children and adolescents at exposure in the population of the Bryansk region after the
Chernobyl accident. Eingereicht bei Environmental Radiat Biophys.
- Ivanov VK, Becker SI, Maksioutov MA, Bronsart von Schellendorff EV, Khait SYe, Korelo
AM, Gorsky AI, Matjash VA, Vlasov OK, Kaidalov OV (2003) German-French Initiative for
Chernobyl, Subproject 3.2.4. Leukaemia Incidence among Children and Adults in the Most
Highly Contaminated Territories of Russia. Final Report.
Ort, Datum Susanne Isabel Becker
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